US20230330062A1 - Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus - Google Patents
Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus Download PDFInfo
- Publication number
- US20230330062A1 US20230330062A1 US18/068,682 US202218068682A US2023330062A1 US 20230330062 A1 US20230330062 A1 US 20230330062A1 US 202218068682 A US202218068682 A US 202218068682A US 2023330062 A1 US2023330062 A1 US 2023330062A1
- Authority
- US
- United States
- Prior art keywords
- ptgdr
- antagonist
- basophils
- sle
- pgd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 149
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims description 111
- 230000009977 dual effect Effects 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 210000003651 basophil Anatomy 0.000 claims description 214
- 238000000034 method Methods 0.000 claims description 52
- 210000005212 secondary lymphoid organ Anatomy 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 20
- -1 2,4,6-trichlorophenyl Chemical group 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- CANCTKXGRVNXFP-UHFFFAOYSA-N 2-[3-[(4-fluorophenyl)sulfonyl-methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]acetic acid Chemical group C1CC(N(C2=CC=CC=C22)CC(O)=O)=C2CC1N(C)S(=O)(=O)C1=CC=C(F)C=C1 CANCTKXGRVNXFP-UHFFFAOYSA-N 0.000 claims description 6
- NXFFJDQHYLNEJK-CYBMUJFWSA-N laropiprant Chemical group C=1([C@@H](CC(O)=O)CCC=1C=1C=C(F)C=C(C2=1)S(=O)(=O)C)N2CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-CYBMUJFWSA-N 0.000 claims description 6
- 229950008292 laropiprant Drugs 0.000 claims description 6
- 230000008816 organ damage Effects 0.000 claims description 5
- 150000003384 small molecules Chemical group 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 105
- 230000014509 gene expression Effects 0.000 description 62
- 206010025135 lupus erythematosus Diseases 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 53
- 238000011282 treatment Methods 0.000 description 49
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 238000000684 flow cytometry Methods 0.000 description 26
- 230000001965 increasing effect Effects 0.000 description 26
- 230000005012 migration Effects 0.000 description 26
- 238000013508 migration Methods 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 201000010099 disease Diseases 0.000 description 24
- 150000002367 halogens Chemical group 0.000 description 24
- 230000001225 therapeutic effect Effects 0.000 description 24
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 20
- 238000007619 statistical method Methods 0.000 description 20
- 230000001419 dependent effect Effects 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 229910052736 halogen Inorganic materials 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 238000009825 accumulation Methods 0.000 description 16
- 230000009266 disease activity Effects 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 208000005777 Lupus Nephritis Diseases 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000010232 migration assay Methods 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- 108010002386 Interleukin-3 Proteins 0.000 description 10
- 102000000646 Interleukin-3 Human genes 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 210000001165 lymph node Anatomy 0.000 description 10
- PXGPLTODNUVGFL-ZWAKLXPCSA-N 11-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-ZWAKLXPCSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102100034258 Sialomucin core protein 24 Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 239000002679 microRNA Substances 0.000 description 9
- 230000007115 recruitment Effects 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 208000017169 kidney disease Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000009368 gene silencing by RNA Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 210000004303 peritoneum Anatomy 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000002619 short lived plasma cell Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- VSRXYLYXIXYEST-KZTWKYQFSA-N 13,14-dihydro-15-ketoprostaglandin D2 Chemical compound CCCCCC(=O)CC[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O VSRXYLYXIXYEST-KZTWKYQFSA-N 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 5
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004180 plasmocyte Anatomy 0.000 description 5
- 150000003163 prostaglandin D2 derivatives Chemical class 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
- 101710082112 Hematopoietic prostaglandin D synthase Proteins 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 4
- 101001117305 Homo sapiens Prostaglandin D2 receptor Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 206010071648 Noninfectious peritonitis Diseases 0.000 description 4
- 102100024212 Prostaglandin D2 receptor Human genes 0.000 description 4
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 4
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 4
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000002975 chemoattractant Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012762 unpaired Student’s t-test Methods 0.000 description 4
- PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 206010015866 Extravasation Diseases 0.000 description 3
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 3
- 241000426682 Salinispora Species 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000003460 anti-nuclear Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008003 autocrine effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036251 extravasation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000003284 homeostatic effect Effects 0.000 description 3
- 102000053523 human CXCR4 Human genes 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 3
- 229960002169 plerixafor Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 2
- JWYIGNODXSRKGP-UHFFFAOYSA-N 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NC(=O)C)=CC=CC=2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 JWYIGNODXSRKGP-UHFFFAOYSA-N 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100025222 CD63 antigen Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 2
- 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000777387 Homo sapiens C-C motif chemokine 3 Proteins 0.000 description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 108010067003 Interleukin-33 Proteins 0.000 description 2
- 102000017761 Interleukin-33 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 229910003827 NRaRb Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 2
- ZBBWXZUXALNRJD-YVLZZHOMSA-N [(2r,3r,4r,5r)-2-[6-(butanoylamino)purin-9-yl]-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] butanoate Chemical compound C1=NC=2C(NC(=O)CCC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC(=O)CCC ZBBWXZUXALNRJD-YVLZZHOMSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 102000043726 human CCL3 Human genes 0.000 description 2
- 102000045341 human CCL5 Human genes 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000017953 prostanoid receptors Human genes 0.000 description 2
- 108050007059 prostanoid receptors Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229950004496 ramatroban Drugs 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- ZWDYQIHXRVDJES-LRTDBIEQSA-N 2-[(1r)-9-[(1r)-1-(4-chlorophenyl)-2,2-difluoroethyl]-6-fluoro-8-methylsulfonyl-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid Chemical compound C1([C@H](C(F)F)N2C=3[C@@H](CC(O)=O)CCCC=3C=3C=C(F)C=C(C2=3)S(=O)(=O)C)=CC=C(Cl)C=C1 ZWDYQIHXRVDJES-LRTDBIEQSA-N 0.000 description 1
- TYICFEDVTALVHL-KUHUBIRLSA-N 2-[(1r)-9-[(1r)-1-(4-chlorophenyl)-2-fluoroethyl]-6-fluoro-8-methylsulfonyl-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid Chemical compound C1([C@H](CF)N2C=3[C@@H](CC(O)=O)CCCC=3C=3C=C(F)C=C(C2=3)S(=O)(=O)C)=CC=C(Cl)C=C1 TYICFEDVTALVHL-KUHUBIRLSA-N 0.000 description 1
- SSLHBZFYMFYOLS-DZGCQCFKSA-N 2-[(1r)-9-[(1s)-1-(4-chlorophenyl)ethyl]-6-fluoro-8-methylsulfonyl-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid Chemical compound C1([C@H](C)N2C3=C(C=C(F)C=C3C=3CCC[C@H](CC(O)=O)C=32)S(C)(=O)=O)=CC=C(Cl)C=C1 SSLHBZFYMFYOLS-DZGCQCFKSA-N 0.000 description 1
- BRVYETPRGCQZJA-WQIZZMQYSA-N 2-[(1r)-9-[(4-chlorophenyl)methyl]-8-[(r)-methylsulfinyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid Chemical compound C=1([C@@H](CC(O)=O)CCCC=1C=1C=CC=C(C2=1)[S@](=O)C)N2CC1=CC=C(Cl)C=C1 BRVYETPRGCQZJA-WQIZZMQYSA-N 0.000 description 1
- OSCRMZVJMAHWLJ-GXTWGEPZSA-N 2-[(3r)-4-[(1s)-1-(4-chlorophenyl)ethyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1([C@H](C)N2C3=C(C=C(F)C=C3C=3CC[C@H](CC(O)=O)C=32)S(C)(=O)=O)=CC=C(Cl)C=C1 OSCRMZVJMAHWLJ-GXTWGEPZSA-N 0.000 description 1
- ZMZNWNTZRWXTJU-UHFFFAOYSA-N 2-[2-(1,3-oxazol-2-yl)-5-[4-(4-propan-2-yloxyphenyl)sulfonylpiperazin-1-yl]phenoxy]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1S(=O)(=O)N1CCN(C=2C=C(OCC(O)=O)C(C=3OC=CN=3)=CC=2)CC1 ZMZNWNTZRWXTJU-UHFFFAOYSA-N 0.000 description 1
- IFYRREHFPGQJQR-UHFFFAOYSA-N 2-[3-[(4-fluorophenyl)sulfonylmethylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]acetic acid Chemical compound C1C=2C3=CC=CC=C3N(CC(=O)O)C=2CCC1NCS(=O)(=O)C1=CC=C(F)C=C1 IFYRREHFPGQJQR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FATGTHLOZSXOBC-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC1=CC=C(C=CC=C2)C2=N1 FATGTHLOZSXOBC-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000037914 B-cell disorder Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100328886 Caenorhabditis elegans col-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010029862 Endolyn Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000930477 Mus musculus Albumin Proteins 0.000 description 1
- 101100272809 Mus musculus Btg3 gene Proteins 0.000 description 1
- 101100232925 Mus musculus Il4 gene Proteins 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 229910003844 NSO2 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 101710201263 Prostaglandin D2 receptor 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- IHAXLPDVOWLUOS-UHFFFAOYSA-N Setipiprant Chemical compound C1=CC=C2C(C(=O)N3CCC=4N(C5=CC=C(F)C=C5C=4C3)CC(=O)O)=CC=CC2=C1 IHAXLPDVOWLUOS-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000043525 human CXCL12 Human genes 0.000 description 1
- 102000046353 human CXCL2 Human genes 0.000 description 1
- 102000055276 human IL3 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 238000012898 one-sample t-test Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950007091 setipiprant Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
- SLE Systemic lupus erythematosus
- LN kidney involvement
- both innate and adaptive immune systems are dysregulated during SLE and synergize to amplify the production of the main lupus pathogenic factors which are autoantibodies mostly directed against nuclear antigens (ANA) such as double stranded DNA (dsDNA). Once aggregated to their antigens and complement factors, these autoantibodies will form circulating immune complexes mediating a chronic inflammation when deposited in the targeted organ.
- ANA nuclear antigens
- dsDNA double stranded DNA
- Flares of the disease are usually controlled by strong immunosuppressive treatments and high dose of corticosteroids.
- Recent clinical trials aimed to decrease auto-antibody production in subjects with SLE by directly targeting the B cell compartment but failed to demonstrate sufficient efficacy.
- Developing new therapeutic strategies to prevent flares to occur represents a big challenge for the biomedical community.
- Basophils are one of the less represented circulating leukocytes and are well known for their involvement in allergic and parasitic diseases. During the past decade, basophils were shown having powerful immune regulatory functions despite their weak representation). It was previously shown that basophils were able to support plasma cell survival and antibody production in vivo while expressing some B cell activating factors such as BAFF (B cell activating factor), CD40L (CD40 ligand or CD154), interleukin (IL)-4 and IL-6 ((Voehringer, D., Nat. Rev. Immunol. 13, 362-375 (2013); Charles, N. et al., Nat. Med. 16, 701-707 (2010)).
- BAFF B cell activating factor
- CD40L CD40 ligand or CD154
- IL-4 and IL-6 interleukin-6
- SLOs secondary lymphoid organs
- CXCL12 C-X-C motif Ligand 12
- CXCL12 is a chemokine secreted mostly by stromal cells from bone marrow, peritoneal cavity, SLOs, and kidneys.
- CXCL12 acts as a homeostatic chemokine by regulating mesenchymal stem cells, B cells and neutrophils physiological distribution via its specific interaction with C-X-C motif Receptor 4 (CXCR4).
- CXCL12 overexpression occurs in inflamed tissues and is pathogenic in cancer and lupus nephritis among other diseases (Wang, A., et al., J. Immunol. 182, 4448-4458 (2009); Balabanian, K., et al., J. Immunol. 170, 3392-3400 (2003); Hummel, S., Van Aken, H. & Zarbock, A. Curr. Opin. Hematol. 21, 29-36 (2014)).
- Prostaglandin D 2 (PGD 2 ) is produced from arachidonic acid by cyclooxygenases and tissue-specific PGD 2 synthases (PGDS).
- PGD 2 contributes to various homeostatic functions and is involved in the onset and resolution of inflammation through its interactions with the two known PGD 2 receptors (PTGDRs): PTGDR-1 (or DP, D prostanoid receptor) and PTGDR-2 (or DP-2, also known as chemoattractant receptor-homologous molecule expressed on T helper type 2 (T H 2) cells, CRTH2).
- Basophils express the highest level of the ubiquitous PTGDR-1 among peripheral blood leukocytes.
- PTGDR-2 expression is more restricted and mediates activation and chemotaxis of basophils, eosinophils and T H 2 CD4 + T cells. The effects of these two receptors can be competitive or cooperative.
- PGD 2 has been involved in allergic and pulmonary diseases, ulcerative colitis, and renal fibrosis.
- Lipocalin-type-PGDS (L-PGDS) was recently found to be expressed de novo in inflamed kidneys (Nagata, N., et al., FEBS J 276, 7146-7158 (2009) and in the urine of active LN patients (Suzuki, M., et al., Pediatr. Res. 65, 530-536 (2009); Somparn, P., et al., J. Proteomics 75, 3240-3247 (2012)).
- basophils were involved in the development of LN both in a spontaneous murine SLE model (Lyn ⁇ / ⁇ mice) and in a small cohort of 42 patients by accumulating in SLOs where they support autoreactive T and B cells through an IgE and IL-4 dependent pathway (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). Since the production of potent basophil activators or chemo-attractants is known to be dysregulated during lupus pathogenesis (Pellefigues, C. & Charles, N., Curr. Opin. Immunol. 25, 704-711 (2013)), mechanisms underlying basophil recruitment to SLOs during SLE were explored.
- the inventors have now identified two new pathways by which basophils get activated during flares of the disease.
- basopenia was a characteristic of SLE patients and was correlated with disease activity. Moreover, as compared to other renal diseases, basopenia was specific of lupus nephritis. This basopenia was associated with a specific expression pattern on basophils of some known and new activation markers. Indeed, CXCR4 expression at the protein level and on the surface of basophils was markedly increased in active patients and associated with basopenia.
- CXCR4 and CD164 led to a dramatically increased sensitivity of SLE basophils to CXCL12-mediated migration ex vivo.
- the inventors demonstrated that migrated basophils were dramatically overexpressing CXCR4 as compared to their “non-migrated” blood basophil counterparts, strongly suggesting that human CXCR4′ basophil extravasation and migration could be induced in vivo by CXCL12, leading to a peripheral basopenia.
- CXCL12 induced a redistribution of CXCR4 basophils at the injection site and in the corresponding draining lymph nodes, demonstrating basophil migration capability to CXCL12 in vivo.
- PGD 2 synthesis was increased in SLE subjects and associated with basopenia.
- This PGD 2 -mediated CXCR4-dependent basophil migration was, at least partially, due to an autocrine effect of PGD 2 upon its synthesis by basophils themselves ex vivo, resulting in an externalization of CXCR4.
- PGD 2 the PGD 2 /PTGDRs axis
- PGD 2 was enhancing CXCR4-dependent basophil recruitment to SLOs during lupus, explaining the flare of the disease observed with repeated PGD 2 injections in lupus-prone mice.
- lupus or “systemic lupus erythematosus” or “SLE” are used in their customary meaning herein and include an autoimmune disorder characterized by the presence of autoantibodies, rash, oral ulcers, serositis, neurological disorders, low blood cell counts, joint pain and swelling.
- Tests used to diagnose include antibody tests (e.g., Antinuclear antibody (ANA) panel, Anti-double strand DNA (dsDNA), Antiphospholipid antibodies, Anti-Smith antibodies): CBC to show low white blood cells, hemoglobin, or platelets; chest x-ray showing pleuritis or pericarditis; kidney biopsy; urinalysis to show blood, casts, or protein in the urine.
- ANA Antinuclear antibody
- dsDNA Anti-double strand DNA
- Anti-Smith antibodies Anti-Smith antibodies
- Lupus nephritis is meant a disorder characterized by an inflammation of the kidney caused by systemic lupus erythematosus (SLE).
- Lupus nephritis is characterized by IgM-, IgG-, and IgA-containing immune complexes deposited in the glomeruli. These immune complexes are formed by autoantibodies with specificity to nuclear components (antinuclear antibodies (ANA)) or to nucleic acids (such as double-stranded DNA (dsDNA)).
- ANA anti-antibodies
- dsDNA double-stranded DNA
- prevention and/or treatment of systemic lupus erythematosus or “LE” encompasses prevention and/or treatment of lupus nephritis.
- treating refers to a therapeutic use (i.e. on a subject having a given disease) and means reversing, alleviating, inhibiting the progress of one or more symptoms of such disorder or condition. Therefore, treatment does not only refer to a treatment that leads to a complete cure of the disease, but also to treatments that slow down the progression of the disease and/or prolong the survival of the subject.
- preventing is meant a prophylactic use (i.e. on a subject susceptible of developing a given disease).
- Prostaglandin D2 or “PDG 2 ” is 9a,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic acid (IUPAC name) (CAS number:41598-07-6).
- PTGDR-1 or “DP” or “D prostanoid receptor” is a receptor for prostaglandin D2 and its activity is mainly mediated by G(s) proteins that stimulate adenylate cyclase, resulting in an elevation of intracellular cAMP.
- An exemplary sequence of human PTGDR-1 protein is available in the UniProt database, under accession number Q13258 (in particular Q13258-1:isoform 1, Entry version 133 of 7 Jan. 2015).
- a complete mRNA sequence encoding PTGDR-1 is available in Genbank under accession number EF577397.1 (release: 122; issue date: 21 Nov. 2014).
- PTGDR-2 or “chemoattractant receptor-homologous molecule expressed on T helper type 2 (TH2) cells” or “CRTH2” or “DP2” is a G-protein-coupled receptor for prostaglandin D2 that is preferentially expressed in CD4+ effector T helper 2 (Th2) cells.
- An exemplary sequence of human PTGDR-2 protein is available in the UniProt database, under accession number Q9Y5Y4 (Entry version 120 of 7 Jan. 2015).
- a complete mRNA sequence encoding PTGDR-2 is available in Genbank under accession number AY507142.1 (release: 122; issue date: 21 Nov. 2014).
- the term “antagonist” refers to any molecule that partially or fully blocks, inhibits, reduces or neutralizes expression and/or biological activity of a target and/or signalling pathway.
- PTGDR-1 antagonist refers to a molecule that partially or fully blocks, inhibits, neutralizes, or interferes with the expression and/or biological activities of a PTGDR-1 protein. This includes, but is not limited to, blocking, inhibiting, reducing, or interfering with PDG 2 /PTGDR-1 interactions.
- PTGDR-1 antagonists include for instance a PDG 2 neutralising antibody, i.e. an antibody which binds to PDG 2 and prevents PDG 2 binding to PTGDR-1.
- PTGDR-2 antagonist refers to a molecule that partially or fully blocks, inhibits, neutralizes, or interferes with the expression and/or biological activities of a PTGDR-2 protein. This includes, but is not limited to, blocking, inhibiting, reducing, or interfering with PDG 2 /PTGDR-2 interactions.
- PTGDR-2 antagonists include for instance a PDG 2 neutralising antibody, i.e. an antibody which binds to PDG 2 and prevents PDG 2 binding to PTGDR-2.
- Suitable antagonist molecules specifically include, but are not limited to biological molecules such as a protein, polypeptide, peptide, antibody, antibody fragment, aptamers, antisense, interfering RNAs, or non-biological large or small molecules (less than 10 kDa), in particular small organic molecules.
- the antagonist may be an inhibitor of PTGDR-1 or PTGDR-2 gene expression.
- Inhibitors of gene expression include antisense oligonucleotides and interfering RNA (iRNA).
- RNA include double-stranded RNA, single-stranded RNA, isolated RNA (partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA), as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the RNA or internally (at one or more nucleotides of the RNA). Nucleotides in the iRNA molecules can also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleotides.
- RNA that mediates RNA interference interacts with the RNA interference machinery such that it directs the machinery to degrade particular mRNAs or to otherwise reduce the expression of the target protein.
- iRNA molecules direct cleavage of specific mRNA to which their sequence corresponds.
- the iRNA molecules may comprise an RNA portion and some additional portion, for example a deoxyribonucleotide portion.
- the total number of nucleotides in the RNA molecule is suitably less than 49 in order to be effective mediators of RNA interference. In preferred RNA molecules, the number of nucleotides is 16 to 29, more preferably 18 to 23, and most preferably 21-23.
- iRNA includes but is not limited to siRNAs, shRNAs, miRNAs, dsRNAs, and other RNA species that can be cleaved in vivo to form siRNAs.
- a “short interfering RNA” or “siRNA” comprises a RNA duplex (double-stranded region) and can further comprises one or two single-stranded overhangs, 3′ or 5′ overhangs.
- a “short hairpin RNA (shRNA)” refers to a segment of RNA that is complementary to a portion of a target gene (complementary to one or more transcripts of a target gene), and has a stem-loop (hairpin) structure.
- miRNAs are endogenously encoded RNAs that are about 22-nucleotide-long, that post-transcriptionally regulate target genes and are generally expressed in a highly tissue-specific or developmental-stage-specific fashion.
- the miR-30 (microRNA 30) architecture can be used to express miRNAs (or siRNAs) from RNA polymerase II promoter-based expression plasmids (Zeng et al, 2005, Methods enzymol. 392:371-380).
- the precursor miRNA molecules may include more than one stem-loop structure.
- the multiple stem-loop structures may be linked to one another through a linker, such as, for example, a nucleic acid linker, a miRNA flanking sequence, other molecules, or some combination thereof.
- Anti-sense oligonucleotides are non-enzymatic nucleic acid molecules that bind to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al, 1993 Nature 365, 566) interactions and alter the activity of the target RNA.
- anti-sense molecules are complementary to a target sequence along a contiguous sequence of the antisense molecule.
- anti-sense DNA can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex.
- antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which immunospecifically binds an antigen.
- the term antibody encompasses not only whole antibody molecules, but also antibody fragments as well as variants (including derivatives) of antibodies and antibody fragments.
- the antibody according to the invention may correspond to a polyclonal antibody, a monoclonal antibody (e.g. a chimeric, humanized or human antibody), a fragment of a polyclonal or monoclonal antibody or a diabody.
- Antibody fragments comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
- antibody fragments include Fv, Fab, F(ab′) 2 , Fab′, Fd, dAb, dsFv, scFv, sc(Fv) 2 , CDRs, diabodies and multi-specific antibodies formed from antibodies fragments.
- “Aptamers” are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity. Such ligands may be isolated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. and Gold L., Science, 1990, 249(4968):505-10. The random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence.
- Peptide aptamers consists of a conformationally constrained antibody variable region displayed by a platform protein, such as E. coli Thioredoxin A that are selected from combinatorial libraries by two hybrid methods (Colas et al., Nature, 1996, 380, 548-50).
- the invention relates to a PTGDR-1 antagonist for use in a method for preventing and/or treating SLE.
- the invention also relates to the use of a PTGDR-1 antagonist for the manufacture of a medicament for preventing and/or treating SLE.
- the invention further relates to a method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist.
- the invention relates to a PTGDR-2 antagonist for use in a method for preventing and/or treating SLE.
- the invention also relates to the use of a PTGDR-2 antagonist for the manufacture of a medicament for preventing and/or treating SLE.
- the invention further relates to a method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-2 antagonist.
- said PTGDR-1 antagonist is a small molecule antagonist.
- Said small molecule antagonist is in particular selected from the group consisting of compounds of formulae I to VI as disclosed hereafter:
- the compounds of formula I have the stereoconfiguration shown below (i.e. the chiral center has the R configuration):
- the compound of formula I or II is laropiprant, i.e. ( ⁇ )-[4-(4-chlorobenzyl)-7-fluoro-5-(methane-sulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid and pharmaceutically acceptable salts thereof:
- Laropiprant is approved by the FDA to inhibit the flushing induced by niacin to treat dyslipidemias.
- Exemplary PTGDR-1 antagonists include, but are not limited to, compounds described as having PGD2 antagonizing activity in PCT Published Applications WO97/00853, WO98/25919, WO01/66520, WO02/094830, WO03/022814, WO03/078409, and WO20041103370; European Patent Applications EP945450, EP944614, and EP 1305286; and U.S. Application Publ. No. 20040220237, 20070244107, and 20080194600, all of which are hereby incorporated by reference in their entirety.
- the PTGDR-1 antagonist is biological molecule antagonist.
- said PTGDR-1 antagonist is an antibody, preferably monoclonal antibody, or antibody fragment, or aptamer directed against PTGDR-1.
- Methods of producing polyclonal or monoclonal antibodies are readily available to the skilled person.
- Said PTGDR-1 antagonist may also be an antisense, or interfering RNA inhibiting PTGDR-1 expression.
- said PTGDR-1 antagonist is an anti-sense oligonucleotide, in particular an anti-sense oligonucleotide comprising or consisting of one of the sequence SEQ ID NO:4415 to SEQ ID No:5483, as disclosed in the international patent application published as WO02/081628.
- said PTGDR-2 antagonist is a small molecule antagonist.
- a PTGDR-2 antagonist is selected from the group consisting of:
- a compound of formula VIII is selected from the group consisting of:
- PTGDR-2 antagonists can be found in the following publications: EP1, 170,594, EP1,435,356 WO2003/066046, WO2003/066047, WO2003/097042, WO2003/097598, WO2003/101961, WO2003/101981, WO2004/007451, WO2004/032848, WO2004/035543, WO20041106302, WO2005/019171, WO2005/054232, WO2005/018529, WO2005/040112, GB2,407,318, WO2005/040114, WO2005/044260, WO2005/095397, WO2005/100321, WO2005/102338, WO2005/123731, WO2006/034419, WO2006/095183, WO2007/107772, WO2008024746, U.S. Pat. No. 7,405,215, each of which is hereby incorporated by reference in its entirety.
- the PTGDR-2 antagonist is biological molecule antagonist.
- said PTGDR-2 antagonist is an antibody, preferably monoclonal antibody, or antibody fragment, or aptamer directed against PTGDR-2.
- said PTGDR-2 antagonist is an antibody depleting PTGDR-2 expressing cells such as described in the international patent application WO2014144865.
- Said PTGDR-2 antagonist may also be an antisense, or interfering RNA inhibiting PTGDR-2 expression.
- a dual PTGDR-1/PTGDR-2 antagonist is an antagonist for which the ratio of antagonist activity against PTGDR-1 and PTGDR-2, respectively, is from 1:10 to 10:1, in particular from 1:50 to 50:1, preferably from 1:100 to 100:1, still preferably from 1:250 to 250:1.
- Dual PTGDR-1/PTGDR-2 antagonists that can be used in the frame of the invention include, for instance, the compounds described in patent application WO 2009/085177:
- said compound of formula VI is AMG 853 (2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenyl sulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid):
- AMG 853 as well as a method of preparing this compound, are also described in Liu et al., ACS Med Chem Lett. 2011 Mar. 2; 2(5):326-30.
- Characterisation of the antagonistic activity of a molecule towards PTGDR-1 and/or PTGDR-2 can be performed, for instance, by methods described in Liu et al., ACS Med Chem Lett. 2011 Mar. 2; 2(5):326-30. These methods include:
- said PTGDR-1 (or PTGDR-2 antagonist) is a dual PTGDR-1/PTGDR-2 antagonist.
- said PTGDR-1 antagonist is not a dual PTGDR-1/PTGDR-2 antagonist.
- the PTGDR-1 antagonist is used either as the sole active ingredient (mono-treatment) for the prevention and/or treatment of SLE, or in combination with at least a PTGDR-2 antagonist (which is neither a dual PTGDR-1/PTGDR-2 antagonist) for the prevention and/or treatment of SLE.
- said PTGDR-2 antagonist is not a dual PTGDR-1/PTGDR-2 antagonist.
- the PTGDR-2 antagonist is used either as the sole active ingredient (mono-treatment) for the prevention and/or treatment of SLE, or in combination with at least a PTGDR-1 antagonist (which is neither a dual PTGDR-1/PTGDR-2 antagonist) for the prevention and/or treatment of SLE.
- the PTGDR-1 antagonist, the PTGDR-2 antagonist, or the combination of PTGDR-1 antagonist and PTGDR-2 antagonist is used in combination with any other standard therapy for the treatment of lupus.
- Therapeutics useful for the treatment of lupus include, but are not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), hydroxychloroquine, corticosteroids, cyckophosphamide, azthioprine, methotrexate, mycophenolate mofetil (MMF) (CelleCept®), belimumab, dehydroepiandrosterone, and rituximab.
- NSAIDs nonsteroidal anti-inflammatory drugs
- hydroxychloroquine corticosteroids
- cyckophosphamide azthioprine
- methotrexate methotrexate
- mycophenolate mofetil (MMF) (CelleCept®) mycophenolate mofetil
- belimumab dehydr
- the PTGDR-1 and/or PTGDR-2 antagonist(s), and optionally further the standard therapeutic for the treatment of lupus are formulated into one or more pharmaceutical composition(s) comprising said PTGDR-1 and/or PTGDR-2 antagonist(s), and optionally further the standard therapeutic for the treatment of lupus, and at least one carrier, excipient or diluent.
- “Pharmaceutically” or “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
- a pharmaceutically acceptable carrier, excipient or diluent refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminium stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyicellulose, polyacrylates, waxes, polyethylene-pol
- the pharmaceutical composition is suitably formulated to be compatible with the intended route of administration.
- suitable routes of administration include topical route, oral route, intranasal route, intraocular route, parenteral route, including for instance intramuscular, subcutaneous, intravenous, intraperitoneal or local injections.
- the oral route can be used, provided that the composition is in a form suitable for oral administration, able to protect the active principle from the gastric and intestinal enzymes.
- the pharmaceutical composition contains carriers that are pharmaceutically acceptable for an injectable formulation.
- carriers may in particular be sterile, isotonic, saline solutions (monosodium phosphate, disodium phosphate, sodium chloride, potassium chloride, calcium chloride or magnesium chloride etc., or mixtures of such salts), or dry, in particular lyophilized, compositions which by means of the addition, as appropriate, of sterilized water or physiological saline, can form injectable solutes.
- the PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in a single pharmaceutical composition, or said PTGDR-1 antagonist, PTGDR-2 antagonist, and standard therapeutic for the treatment of lupus, are formulated in separate pharmaceutical compositions for simultaneous use, separate use, or use spread over time.
- the invention also provides for a pharmaceutical composition
- a pharmaceutical composition comprising a PTGDR-1 antagonist and a PTGDR-2 antagonist; or a dual PTGDR-1/PTGDR-2 antagonist; a PTGDR-1 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-1 antagonist, a PTGDR-2 antagonist, and a standard therapeutic for the treatment of lupus; or a dual PTGDR-1/PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus, for use in a method for preventing and/or treating SLE.
- a method for preventing and/or treating SLE in a patient in need thereof comprises administering said patient with a PTGDR-1 antagonist and a PTGDR-2 antagonist, or a dual PTGDR-1/PTGDR-2 antagonist.
- a standard therapeutic for the treatment of lupus is further step administered with the PTGDR-1 antagonist and PTGDR-2 antagonist, or with the dual PTGDR-1/PTGDR-2 antagonist.
- a method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist or a PTGDR-2 antagonist, and with a standard therapeutic for the treatment of lupus also makes part of the invention.
- the invention also relates to PTGDR-1 antagonist and a PTGDR-2 antagonist; or a dual PTGDR-1/PTGDR-2 antagonist; a PTGDR-1 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-1 antagonist, a PTGDR-2 antagonist, and a standard therapeutic for the treatment of lupus; or a dual PTGDR-1/PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus, for use as a combined preparation for simultaneous use, separate use, or use spread over time, in a method for preventing and/or treating SLE.
- the methods of preventing and/or treating SLE according to the invention preferably use an effective amount of PTGDR-1 and/or PTGDR-2 antagonist and/or standard therapeutic for the treatment of lupus.
- an amount is intended to mean an amount sufficient to prevent and/or treat a given disease. It will be appreciated that this amount will vary with the effectiveness of therapeutic agent(s) employed, with the nature of any carrier used, with the seriousness of the disease and the age of the patient. The determination of appropriate amounts for any given composition is within the skill in the art, through standard series of tests designed to assess appropriate therapeutic levels.
- the PTGDR-1 antagonist and/or PTGDR-2 antagonist prevent(s) basophil homing to secondary lymphoid organs.
- the PTGDR-1 antagonist and/or PTGDR-2 antagonist prevents, limits the extent or reduces the increase in autoantibody titers and/or the occurrence of SLE flares.
- the PTGDR-1 antagonist and/or PTGDR-2 antagonist also prevents, limits the extent or reduces the occurrence organ damages, in particular to kidneys, heart, lungs, and brain.
- the PTGDR-1 antagonist and/or PTGDR-2 antagonist prevents, limits the extent or reduces the occurrence of lupus nephritis.
- FIG. 1 Human blood basophil gating strategy and activation status In function of SLE disease activity.
- FIG. 2 Basopenia and basophil activation status correlate with disease activity and are specific for lupus nephritis among other active renal diseases.
- FIG. 3 PGD 2 /PTGDRs and CXCL12/CXCR4 axes contribute to SLE patient specific basophil phenotype
- FIG. 4 Associations between plasma 11 ⁇ -PGF2 ⁇ & CXCL12 titers, basophil CXCR4 & CD164 expression levels and lupus specific basopenia
- FIG. 5 CXCR4-mediated basophil migration ex vivo and in vivo is enhanced by PGD 2
- FIG. 6 Suboptimal IgE-mediated basophil activation leads to increased PTGDR-2 expression on human basophils.
- FIG. 7 PGD 2 Is sufficient to enhance the CXCL12-dependent basophil homing to SLOs occurring In lupus-prone mice
- FIG. 8 CXCL12 or PGD2 Ip Injection In mice Induce a CXCR4-dependent basophil accumulation In SLOs and peritoneum.
- FIG. 9 cAMP and PTGDRs specific agonist effects on CXCR4 expression by mouse spleen basophils ex vivo.
- FIG. 10 Blockade of basophil accumulation In SLOs dampens lupus-like disease activity
- FIG. 11 Blockade of basophil accumulation in SLOs dampens lupus-like disease activity
- FIG. 12 Targeting PTGDRs blocks CXCR4-mediated basophil accumulation In SLOs and reduces the lupus-like disease activity.
- FIG. 13 Treatment with PTGDRs antagonists reduces specifically basophil accumulation in SLOs leading to reduced short-lived plasma cell number and serum ANA titers.
- FIG. 14 Graphical abstract
- mice C57BL/6J wild-type mice were purchased from Charles River Laboratories (L'Arbresle, France) and Lyn ⁇ / ⁇ mice on a pure C57BL/6 background were bred in our animal facility.
- mice were aged for a minimum of 40 weeks before treatment and analysis.
- young mice were between 8 and 12 weeks old, unless otherwise specified. Mice were maintained in specific pathogen-free conditions, used in accordance with French and European guidelines and approved by local ethical committee and by the Department of Research of the French government under the animal study proposal 02484.01.
- Lupus activity was assessed by SELENA-SLEDAI (Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Disease Activity Index) scores. Based on the SLEDAI score, lupus activity was classified as inactive (0-1), mild (2-4) and active (>4). All samples were collected in heparin blood collection tubes and processed within 4 hours. A written informed consent was obtained from all subjects. Active lupus nephritis subjects were defined by histologically active classes Ill or IV+/ ⁇ V nephritis, in accordance with the ISN/RPS classification (Weening, J. J., et al., J. Am. Soc. Nephrol. 15, 241-250 (2004)).
- 11 ⁇ -Prostaglandin F 2 ⁇ enzyme immunoassay (EIA) kits were from Cayman Chemicals (Ann Arbor, MI).
- Mouse ANA enzyme linked immunosorbent assay (ELISA) kits were from ADI (San Antonio, TX).
- Human and mice CXCL12 ELISA kits were from R&D Systems (Minneapolis, MN). Assessment of cytokine content in the kidney was previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)).
- Mouse IL4 and IL1 ⁇ ELISA kits were from BioLegend (San Diego, CA).
- Mouse IgE Quantification ELISA kits were from Bethyl Laboratories (Montgomery, TX).
- Human basophils were purified to >95% by negative selection with the Human Basophils Enrichment kit (Stemcell Technologies, Grenoble, France) for culture, stimulation and chemotaxis experiments.
- human basophils were enriched to 3-5% by negative selection with the Human PE positive selection kit (Stemcell Technologies) by using a cocktail of PE-conjugated anti-CD3, CD19 and CD89 (BioLegend). These kits were used following manufacturer instructions.
- Basophils were enriched to 3-5% as described above and frozen at ⁇ 80° C. in 90% FCS 10% dimethyl sulfoxide until enough samples were collected. Thawed cells were stained, fixed (IC fixation buffer, eBioscience) and permeabilized (Wash Perm Buffer, BioLegend) following the manufacturers' instructions. Anti-human CXCR4 or its isotype (BioLegend) were used for intracellular staining. DAPI was added prior to cytometry analysis. Basophils were gated as Singlets cells/Focus high/DAPI high/PE ⁇ CD123 + Fc ⁇ RI ⁇ + CD303 ⁇ .
- CXCR4 expression was determined for each basophil as the ratio of the geometric mean of their CXCR4 intensity on the mean basophil CXCR4 FMO (Fluorescence Minus One) intensity. Internalization scores were determined using Fc ⁇ RI ⁇ staining as a membrane marker and CXCR4 staining as the probe. For each sample, externalization score corresponds to [1 ⁇ internalization score]. All analyses were performed using the ImageStream X Mark II imaging flow cytometer and the IDEAS v6 software (AMNIS).
- Human basophils and mouse splenocytes were cultured in culture medium (RPMI 1640 with Glutamax and 20 mM HEPES, 1 mM Na-pyruvate, non-essential amino acids 1X (all from Life Technologies, Saint-Aubin, France), 100 ⁇ g/ml streptomycin and 100 U/ml penicillin (GE Healthcare, Vélizy, France) and 37.5 ⁇ M ⁇ -mercaptoethanol (Sigma-Aldrich, MO)) supplemented with 20% heat-inactivated fetal calf serum at 37° C. and 5% CO 2 .
- culture medium RPMI 1640 with Glutamax and 20 mM HEPES, 1 mM Na-pyruvate, non-essential amino acids 1X (all from Life Technologies, Saint-Aubin, France), 100 ⁇ g/ml streptomycin and 100 U/ml penicillin (GE Healthcare, Vélizy, France) and 37.5 ⁇ M ⁇ -mercaptoethanol (Sigma
- 18 hours-long stimulation prior to migration assays were done in culture medium at 1 ⁇ 10 6 cells per mL by adding 1 nM of IL-3 (Peprotech), 1 ⁇ M of prostaglandin D2 (PGD 2 ), 1 ⁇ M of the PTGDR-1 specific agonist BW245c, 1 ⁇ M of the PTGDR-2 specific agonist 13,14-dihydro-15-keto Prostaglandin D 2 (DK-PGD 2 ) (all from Cayman chemicals) or 5 ng/mL of anti-IgE (mouse anti-human IgE or rat anti-mouse IgE, both from Thermo Scientific). All cells were washed twice before any migration assay. Control conditions were always with the same vehicle concentration as stimulated conditions.
- Migration assays were performed in culture medium supplemented with 0.1% bovine serum albumin (BSA, Sigma-Aldrich) in Transwell 5 ⁇ m polycarbonate permeable support 6.5 mm inserts (Corning, New York, NY) for 3 hours at 37° C. and 5% CO 2 with 1 ⁇ 10 5 purified basophils or 2 ⁇ 10 5 enriched basophils at 1 ⁇ 10 6 cells per mL. Purified or enriched basophils from the upper and bottom chambers were counted at the end of the assay. Basophil content and phenotype was determined by flow cytometry by analyzing more than 100 basophils. Purification or enrichment of human basophils didn't show any difference in the measured migration for all tested chemokines.
- BSA bovine serum albumin
- Migration was defined as the ratio between the number of basophils in the bottom chamber and the number of basophils in the upper plus the bottom chambers.
- Spontaneous migration was defined as the migration observed without any chemokine in the bottom chamber.
- Corrected migration was defined as the difference between specific and spontaneous migration.
- Human IL-3 300 ⁇ M (Peprotech), human CCL3, CCL5, and CXCL12: 50 nM; CXCL2 (all from BioLegend) and PGD 2 (Cayman chemicals): 100 nM.
- Migration to human CCL3, CCL5, CXCL2, and PGD 2 was done in the presence of IL-3 at 300 ⁇ M in both chambers.
- IL-3 was added in both chambers to the same concentration and compared to the spontaneous migration observed without IL-3. Effects of 24 hours incubation with IL-3 or PGD2 (as described above) on basophil apoptosis were estimated by using the FITC Annexin V Apoptosis Detection Kit from BD Biosciences and used accordingly to manufacturer's instructions.
- CXCL12-induced basophil in vivo migration assays 200 ⁇ L of PBS containing 100 ng of murine CXCL12 or PBS alone were injected intraperitoneally (ip) in 8-12 weeks old WT mice.
- PGD 2 -induced basophil in vivo migration assays 100 ⁇ L of PBS (with 2 ⁇ L of ethanol) alone, or PBS ⁇ 20 nmoles of PGD 2 ⁇ 200 ⁇ g of AMD3100 (all from Cayman Chemicals) were injected ip in 8-12 weeks old Lyn ⁇ / ⁇ mice.
- mice were euthanized and peritoneal lavage, blood, mesenteric lymph nodes and spleen were collected and prepared for FACS analysis as previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)).
- PGD 2 injections 12 weeks old Lyn ⁇ / ⁇ mice were injected ip with 20 nmoles of PGD 2 or vehicle in PBS, every two days for 10 days, for a total of 6 injections. Mice were analyzed the day following the last injection.
- mice For treatment with PTGDRs antagonists, aged WT and Lyn ⁇ / ⁇ mice were treated by oral doses of 5 mg/kg of Laropiprant and CAY10471 (Cayman chemicals) or equivalent dose of ethanol (vehicle) in tap water twice a day for ten days. Then, mice were euthanized and blood, plasma, spleen, bone marrow, kidneys and lymph nodes (cervical, brachial, inguinal and mesenteric) were analyzed as previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). The treatment didn't affect weight and cell numbers in the different organs. Cell viability was assessed by the utilization of Ghost Dye Violet 510 (Tonbo, San Diego, CA).
- Kidney preparation for immunofluorescence analysis of C3 and IgG deposits was as previously described (Charles, N et al. Nat. Med., 2010, 16, 701-707, 2159). Quantification of C3 and IgG deposits was realized by using ImageJ software (v1.49p, NIH, USA). A minimum of 20 glomeruli was quantified per kidney. For assessment of kidney function the albumin/creatinine ratio (ACR) was determined. Urine was collected from each mouse before and after treatment. The albumin concentration was measured with a mouse albumin ELISA (Bethyl laboratories, Montgomery, TX). A creatinine assay (R&D systems, Minneapolis, MN) was used to determine urine creatinine concentrations. Results are expressed as a fold increase corresponding to the ratio of the ACR after/before treatment.
- SLE basophils did not display a degranulated phenotype (as measured by their CD63 expression level, FIG. 1 c ).
- Thymic Stromal Lymphopoietin Receptor TLP-R
- IL-33 receptor T1/ST2
- CCR C-C motif ligand receptor 4
- CCR6 and CCR7 could not be detected on basophils (Table 2).
- CXCR4 expression was increased on basophils from all SLE individuals, but active SLE patients showed an even more marked increase (Table 2, FIG. 3 d ).
- CXCL12 plasma titers followed the same pattern of increase as its receptor did on basophils ( FIG. 3 e ).
- high CXCL12 titers were associated with a more pronounced basopenia ( FIG. 4 c ).
- CD164 is a transmembrane syalomucin enhancing sensitivity to CXCL12 when associated to CXCR4 and is also known as a human basophil activation marker.
- Basophils are known to express CXCR4 mostly intracellularly. Analyses by imaging flow cytometry showed that SLE patient basophils had an increased CXCR4 content and that it was more externalized than in HC basophils (data not shown).
- CXCL12 is described as one of the most overexpressed gene during peritoneal dialysis and is actively secreted together with PGD 2 during peritonitis.
- CXCR4 expression was dramatically increased on human basophils recruited to the inflamed peritoneum as compared to their blood counterparts (data not shown). This basophil recruitment was associated with a peripheral basopenia (data not shown), as previously shown in active chronic idiopathic urticarial (Jain, S.
- PGD 2 /PTGDRs Axis Enhances CXCR4-Dependent Basophil Migration During Lupus
- CXCL12 is described as one of the most overexpressed gene during peritoneal dialysis and is actively secreted together with PGD 2 during peritonitis.
- CXCR4 was found to be dramatically increased on human basophils recruited to the inflamed peritoneum as compared to their blood counterparts ( FIG. 5 e ). This basophil recruitment was associated with a peripheral basopenia (supplementary FIG. 5 b ), as previously shown in active chronic idiopathic urticaria. This demonstrated that human CXCR4* basophils can migrate in vivo to CXCL12- and PGD 2 -secreting inflamed tissues.
- CXCR4 expression was increased on WT and Lyn ⁇ / ⁇ basophils from SLOs as compared to their blood counterparts suggesting an involvement of CXCR4 in their accumulation in these organs ( FIG. 7 b ).
- CXCL12 intraperitoneal (ip) injection in WT mice induced in vivo basophil migration to the injection site ( FIG. 7 c ) and to the draining mesenteric lymph nodes (mLN) ( FIG. 8 a ).
- PTGDR-1 is known to induce cyclic adenosine monophosphate (cAMP) production upon engagement by PGD 2 .
- cAMP cyclic adenosine monophosphate
- db-cAMP membrane permeable cAMP
- Basophils externalized CXCR4 upon db-cAMP exposure FIG. 9 a
- FIG. 9 b Basophils externalized CXCR4 upon db-cAMP exposure
- PGD 2 was unable to induce enough cAMP through PTGDR-1 to lead to CXCR4 externalization by T cells in these settings, unlike what was observed on basophils ( FIG. 9 a,b ).
- Dose response experiments of each PTGDR specific agonists in the presence or not of H-PGDS inhibitor suggested again that both PTGDRs were able to cooperatively induce CXCR4 externalization on basophils through PTGDR-2-induced PGD 2 synthesis acting in an autocrine way on PTGDR-1-mediated cAMP production ( FIG. 9 c ).
- PGD 2 axis Targeting the PGD 2 axis reduces CXCR4-mediated basophil accumulation in SLOs and dampens lupus-like disease
- CXCL12/CXCR4 axis in murine lupus has already been described and showed some efficacy on disease activity (Balabanian, K., et al., J. Immunol. 170, 3392-3400 (2003), Wang, A., et al., J. Immunol. 182, 4448-4458 (2009)).
- CXCR4 antagonism (with AMD3100), initially developed as an anti-HIV drug, is known to induce a release of hematopoietic stem cells and interfere with homeostatic functions (Devi, S. et al. J. Exp. Med. 210, 2321-2336, (2013), Hummel, S. et al., Curr. Opin.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
Figure: none
Description
- The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
- Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease which can affect various organs such as joints and skin and be lethal when kidney involvement (lupus nephritis, LN) is not controlled. If considered as a B cell disease, both innate and adaptive immune systems are dysregulated during SLE and synergize to amplify the production of the main lupus pathogenic factors which are autoantibodies mostly directed against nuclear antigens (ANA) such as double stranded DNA (dsDNA). Once aggregated to their antigens and complement factors, these autoantibodies will form circulating immune complexes mediating a chronic inflammation when deposited in the targeted organ. Flares of the disease are usually controlled by strong immunosuppressive treatments and high dose of corticosteroids. Recent clinical trials aimed to decrease auto-antibody production in subjects with SLE by directly targeting the B cell compartment but failed to demonstrate sufficient efficacy. Developing new therapeutic strategies to prevent flares to occur represents a big challenge for the biomedical community.
- Basophils are one of the less represented circulating leukocytes and are well known for their involvement in allergic and parasitic diseases. During the past decade, basophils were shown having powerful immune regulatory functions despite their weak representation). It was previously shown that basophils were able to support plasma cell survival and antibody production in vivo while expressing some B cell activating factors such as BAFF (B cell activating factor), CD40L (CD40 ligand or CD154), interleukin (IL)-4 and IL-6 ((Voehringer, D., Nat. Rev. Immunol. 13, 362-375 (2013); Charles, N. et al., Nat. Med. 16, 701-707 (2010)). This immunomodulatory role is associated with their ability to accumulate in secondary lymphoid organs (SLOs) where they can help T and B cells in differentiation and maturation (Charles, N. et al., Nat. Med. 16, 701-707 (2010); Leyva-Castillo, J. M., et al., Nat Commun 4, 2847 (2013); Otsuka, A., et al., Nat Commun 4, 1739 (2013)). Mechanisms leading to SLOs basophil accumulation are poorly understood.
- C-X-C motif Ligand 12 (CXCL12) is a chemokine secreted mostly by stromal cells from bone marrow, peritoneal cavity, SLOs, and kidneys. CXCL12 acts as a homeostatic chemokine by regulating mesenchymal stem cells, B cells and neutrophils physiological distribution via its specific interaction with C-X-C motif Receptor 4 (CXCR4). CXCL12 overexpression occurs in inflamed tissues and is pathogenic in cancer and lupus nephritis among other diseases (Wang, A., et al., J. Immunol. 182, 4448-4458 (2009); Balabanian, K., et al., J. Immunol. 170, 3392-3400 (2003); Hummel, S., Van Aken, H. & Zarbock, A. Curr. Opin. Hematol. 21, 29-36 (2014)).
- Prostaglandin D2 (PGD2) is produced from arachidonic acid by cyclooxygenases and tissue-specific PGD2 synthases (PGDS). PGD2 contributes to various homeostatic functions and is involved in the onset and resolution of inflammation through its interactions with the two known PGD2 receptors (PTGDRs): PTGDR-1 (or DP, D prostanoid receptor) and PTGDR-2 (or DP-2, also known as chemoattractant receptor-homologous molecule expressed on T helper type 2 (TH2) cells, CRTH2). Basophils express the highest level of the ubiquitous PTGDR-1 among peripheral blood leukocytes. PTGDR-2 expression is more restricted and mediates activation and chemotaxis of basophils, eosinophils and
T H2 CD4+ T cells. The effects of these two receptors can be competitive or cooperative. PGD2 has been involved in allergic and pulmonary diseases, ulcerative colitis, and renal fibrosis. Lipocalin-type-PGDS (L-PGDS) was recently found to be expressed de novo in inflamed kidneys (Nagata, N., et al., FEBS J 276, 7146-7158 (2009) and in the urine of active LN patients (Suzuki, M., et al., Pediatr. Res. 65, 530-536 (2009); Somparn, P., et al., J. Proteomics 75, 3240-3247 (2012)). - However, the PGD2/PTGDRs axis has not been characterized in SLE.
- In this respect, the international patent application WO 2009/085177 has disclosed dual PTGDR-1/PTGDR-2 antagonists and suggested that these antagonists could be useful in the prevention and/or treatment of a list of diseases including SLE. However the only therapeutic effect concretely evaluated in this document is against asthma. The proposed prevention and/or treatment of SLE is not substantiated.
- The inventors recently showed that basophils were involved in the development of LN both in a spontaneous murine SLE model (Lyn−/− mice) and in a small cohort of 42 patients by accumulating in SLOs where they support autoreactive T and B cells through an IgE and IL-4 dependent pathway (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). Since the production of potent basophil activators or chemo-attractants is known to be dysregulated during lupus pathogenesis (Pellefigues, C. & Charles, N., Curr. Opin. Immunol. 25, 704-711 (2013)), mechanisms underlying basophil recruitment to SLOs during SLE were explored.
- The inventors have now identified two new pathways by which basophils get activated during flares of the disease.
- Tissue chronic inflammation is leading to the secretion of basophil activating factors which systemic concentrations are dysregulated during lupus. In a new larger cohort of individuals with SLE, the inventors confirmed that basopenia was a characteristic of SLE patients and was correlated with disease activity. Moreover, as compared to other renal diseases, basopenia was specific of lupus nephritis. This basopenia was associated with a specific expression pattern on basophils of some known and new activation markers. Indeed, CXCR4 expression at the protein level and on the surface of basophils was markedly increased in active patients and associated with basopenia.
- The inventors found that disease activity and basopenia were tightly linked together and to PGD2/PTGDRs and CXCL12/CXCR4 axes.
- Beyond their altered expression pattern on active lupus subject basophils, CXCR4 and CD164 led to a dramatically increased sensitivity of SLE basophils to CXCL12-mediated migration ex vivo. In non-sterile peritonitis patients, the inventors demonstrated that migrated basophils were dramatically overexpressing CXCR4 as compared to their “non-migrated” blood basophil counterparts, strongly suggesting that human CXCR4′ basophil extravasation and migration could be induced in vivo by CXCL12, leading to a peripheral basopenia. In mice, CXCL12 induced a redistribution of CXCR4 basophils at the injection site and in the corresponding draining lymph nodes, demonstrating basophil migration capability to CXCL12 in vivo. These migration abilities, both in human and mice, were enabled in vivo and ex vivo by the PGD2/PTGDRs axis.
- Furthermore, the inventors demonstrated that PGD2 synthesis was increased in SLE subjects and associated with basopenia. This PGD2-mediated CXCR4-dependent basophil migration was, at least partially, due to an autocrine effect of PGD2 upon its synthesis by basophils themselves ex vivo, resulting in an externalization of CXCR4. In particular, both in subjects with SLE and in Lyn−/− mice, the inventors found that PGD2 (the PGD2/PTGDRs axis) was enhancing CXCR4-dependent basophil recruitment to SLOs during lupus, explaining the flare of the disease observed with repeated PGD2 injections in lupus-prone mice. These data underline the CXCR4-mediated pathogenic effect of PGD2 during lupus pathogenesis, identifying both axes as putative therapeutic targets.
- The inventors thus concluded that altering these axes in SLE patients using PTGDRs specific antagonists should break the basophil-dependent autoantibody production and kidney inflammation as showed in the Lyn−/− lupus-like mouse model, and should limit SLE flares and long term organ damages by preventing basophil homing to SLOs.
- The inventors demonstrated that antagonizing PTGDRs in vivo in a lupus-like mouse model prevented the CXCR4-dependent basophil recruitment in SLOs without impacting other cell type proportions but the short lived plasma cells. This treatment achieved to dampen short-lived plasma cell number, renal inflammation, and autoantibodies titers in only 10 days.
- The terms “lupus” or “systemic lupus erythematosus” or “SLE” are used in their customary meaning herein and include an autoimmune disorder characterized by the presence of autoantibodies, rash, oral ulcers, serositis, neurological disorders, low blood cell counts, joint pain and swelling. Tests used to diagnose include antibody tests (e.g., Antinuclear antibody (ANA) panel, Anti-double strand DNA (dsDNA), Antiphospholipid antibodies, Anti-Smith antibodies): CBC to show low white blood cells, hemoglobin, or platelets; chest x-ray showing pleuritis or pericarditis; kidney biopsy; urinalysis to show blood, casts, or protein in the urine.
- By “lupus nephritis” is meant a disorder characterized by an inflammation of the kidney caused by systemic lupus erythematosus (SLE). Lupus nephritis is characterized by IgM-, IgG-, and IgA-containing immune complexes deposited in the glomeruli. These immune complexes are formed by autoantibodies with specificity to nuclear components (antinuclear antibodies (ANA)) or to nucleic acids (such as double-stranded DNA (dsDNA)).
- Accordingly, as used herein, prevention and/or treatment of systemic lupus erythematosus or “LE” encompasses prevention and/or treatment of lupus nephritis.
- In the context of the invention, the term “treating” or “treatment”, refers to a therapeutic use (i.e. on a subject having a given disease) and means reversing, alleviating, inhibiting the progress of one or more symptoms of such disorder or condition. Therefore, treatment does not only refer to a treatment that leads to a complete cure of the disease, but also to treatments that slow down the progression of the disease and/or prolong the survival of the subject.
- By “preventing” is meant a prophylactic use (i.e. on a subject susceptible of developing a given disease).
- “Prostaglandin D2” or “PDG2” is 9a,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic acid (IUPAC name) (CAS number:41598-07-6).
- “PTGDR-1” or “DP” or “D prostanoid receptor” is a receptor for prostaglandin D2 and its activity is mainly mediated by G(s) proteins that stimulate adenylate cyclase, resulting in an elevation of intracellular cAMP. An exemplary sequence of human PTGDR-1 protein is available in the UniProt database, under accession number Q13258 (in particular Q13258-1:
isoform 1, Entry version 133 of 7 Jan. 2015). A complete mRNA sequence encoding PTGDR-1 is available in Genbank under accession number EF577397.1 (release: 122; issue date: 21 Nov. 2014). - “PTGDR-2” or “chemoattractant receptor-homologous molecule expressed on T helper type 2 (TH2) cells” or “CRTH2” or “DP2” is a G-protein-coupled receptor for prostaglandin D2 that is preferentially expressed in CD4+ effector T helper 2 (Th2) cells. An exemplary sequence of human PTGDR-2 protein is available in the UniProt database, under accession number Q9Y5Y4 (Entry version 120 of 7 Jan. 2015). A complete mRNA sequence encoding PTGDR-2 is available in Genbank under accession number AY507142.1 (release: 122; issue date: 21 Nov. 2014).
- As used herein, the term “antagonist” refers to any molecule that partially or fully blocks, inhibits, reduces or neutralizes expression and/or biological activity of a target and/or signalling pathway.
- “PTGDR-1 antagonist” refers to a molecule that partially or fully blocks, inhibits, neutralizes, or interferes with the expression and/or biological activities of a PTGDR-1 protein. This includes, but is not limited to, blocking, inhibiting, reducing, or interfering with PDG2/PTGDR-1 interactions. PTGDR-1 antagonists include for instance a PDG2 neutralising antibody, i.e. an antibody which binds to PDG2 and prevents PDG2 binding to PTGDR-1.
- “PTGDR-2 antagonist” refers to a molecule that partially or fully blocks, inhibits, neutralizes, or interferes with the expression and/or biological activities of a PTGDR-2 protein. This includes, but is not limited to, blocking, inhibiting, reducing, or interfering with PDG2/PTGDR-2 interactions. PTGDR-2 antagonists include for instance a PDG2 neutralising antibody, i.e. an antibody which binds to PDG2 and prevents PDG2 binding to PTGDR-2.
- Suitable antagonist molecules specifically include, but are not limited to biological molecules such as a protein, polypeptide, peptide, antibody, antibody fragment, aptamers, antisense, interfering RNAs, or non-biological large or small molecules (less than 10 kDa), in particular small organic molecules.
- The antagonist may be an inhibitor of PTGDR-1 or PTGDR-2 gene expression. Inhibitors of gene expression include antisense oligonucleotides and interfering RNA (iRNA).
- The term “iRNA” include double-stranded RNA, single-stranded RNA, isolated RNA (partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA), as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the RNA or internally (at one or more nucleotides of the RNA). Nucleotides in the iRNA molecules can also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleotides. Collectively, all such altered iRNA compounds are referred to as analogs or analogs of naturally-occurring RNA. A iRNA needs only be sufficiently similar to natural RNA that it has the ability to mediate RNA interference. As used herein the phrase “mediate RNA Interference” refers to and indicates the ability to distinguish which mRNA are to be affected by the RNA interference machinery or process. RNA that mediates RNA interference interacts with the RNA interference machinery such that it directs the machinery to degrade particular mRNAs or to otherwise reduce the expression of the target protein. In one embodiment, iRNA molecules direct cleavage of specific mRNA to which their sequence corresponds. It is not necessary that there be perfect correspondence of the sequences, but the correspondence must be sufficient to enable the iRNA to direct RNA interference inhibition by cleavage or lack of expression of the target mRNA. The iRNA molecules may comprise an RNA portion and some additional portion, for example a deoxyribonucleotide portion. The total number of nucleotides in the RNA molecule is suitably less than 49 in order to be effective mediators of RNA interference. In preferred RNA molecules, the number of nucleotides is 16 to 29, more preferably 18 to 23, and most preferably 21-23.
- As indicated above, the term iRNA includes but is not limited to siRNAs, shRNAs, miRNAs, dsRNAs, and other RNA species that can be cleaved in vivo to form siRNAs.
- A “short interfering RNA” or “siRNA” comprises a RNA duplex (double-stranded region) and can further comprises one or two single-stranded overhangs, 3′ or 5′ overhangs.
- A “short hairpin RNA (shRNA)” refers to a segment of RNA that is complementary to a portion of a target gene (complementary to one or more transcripts of a target gene), and has a stem-loop (hairpin) structure.
- “MicroRNAs” or “miRNAs” are endogenously encoded RNAs that are about 22-nucleotide-long, that post-transcriptionally regulate target genes and are generally expressed in a highly tissue-specific or developmental-stage-specific fashion. One can design and express artificial miRNAs based on the features of existing miRNA genes. The miR-30 (microRNA 30) architecture can be used to express miRNAs (or siRNAs) from RNA polymerase II promoter-based expression plasmids (Zeng et al, 2005, Methods enzymol. 392:371-380). In some instances the precursor miRNA molecules may include more than one stem-loop structure. The multiple stem-loop structures may be linked to one another through a linker, such as, for example, a nucleic acid linker, a miRNA flanking sequence, other molecules, or some combination thereof.
- Anti-sense oligonucleotides are non-enzymatic nucleic acid molecules that bind to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al, 1993 Nature 365, 566) interactions and alter the activity of the target RNA. Typically, anti-sense molecules are complementary to a target sequence along a contiguous sequence of the antisense molecule. In addition, anti-sense DNA can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex.
- The term “antibody” refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which immunospecifically binds an antigen. As such, the term antibody encompasses not only whole antibody molecules, but also antibody fragments as well as variants (including derivatives) of antibodies and antibody fragments. In particular, the antibody according to the invention may correspond to a polyclonal antibody, a monoclonal antibody (e.g. a chimeric, humanized or human antibody), a fragment of a polyclonal or monoclonal antibody or a diabody.
- “Antibody fragments” comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fv, Fab, F(ab′)2, Fab′, Fd, dAb, dsFv, scFv, sc(Fv)2, CDRs, diabodies and multi-specific antibodies formed from antibodies fragments.
- “Aptamers” are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity. Such ligands may be isolated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. and Gold L., Science, 1990, 249(4968):505-10. The random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence. Possible modifications, uses and advantages of this class of molecules have been reviewed in Jayasena S. D., Clin. Chem., 1999, 45(9):1628-50. Peptide aptamers consists of a conformationally constrained antibody variable region displayed by a platform protein, such as E. coli Thioredoxin A that are selected from combinatorial libraries by two hybrid methods (Colas et al., Nature, 1996, 380, 548-50).
- Throughout the instant application, the term “comprising” is to be interpreted as encompassing all specifically mentioned features as well optional, additional, unspecified ones. As used herein, the use of the term “comprising” also discloses the embodiment wherein no features other than the specifically mentioned features are present (i.e. “consisting of”).
- Furthermore the indefinite article “a” or “an” does not exclude a plurality.
- The invention relates to a PTGDR-1 antagonist for use in a method for preventing and/or treating SLE. The invention also relates to the use of a PTGDR-1 antagonist for the manufacture of a medicament for preventing and/or treating SLE. The invention further relates to a method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist.
- According to another aspect, the invention relates to a PTGDR-2 antagonist for use in a method for preventing and/or treating SLE. The invention also relates to the use of a PTGDR-2 antagonist for the manufacture of a medicament for preventing and/or treating SLE. The invention further relates to a method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-2 antagonist.
- PTGDR-1 antagonists
- According to an embodiment, said PTGDR-1 antagonist is a small molecule antagonist.
- Numerous PTGDR-1 antagonists have been described in the art.
- Said small molecule antagonist is in particular selected from the group consisting of compounds of formulae I to VI as disclosed hereafter:
-
- (i) Compounds of formula (I) as described in patent application WO03062200:
-
- and pharmaceutically acceptable salts thereof, wherein
- n is 0 or 1; m is 1, 2 or 3; R1 is H, C1-C3 alkyl, halogenated C1-C3 alkyl or cyclopropyl; R2 is 4-chlorophenyl or 2,4,6-trichlorophenyl.
- Preferably, the compounds of formula I have the stereoconfiguration shown below (i.e. the chiral center has the R configuration):
- In particular, the compound of formula I or II is laropiprant, i.e. (−)-[4-(4-chlorobenzyl)-7-fluoro-5-(methane-sulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid and pharmaceutically acceptable salts thereof:
- Laropiprant is approved by the FDA to inhibit the flushing induced by niacin to treat dyslipidemias.
-
- (ii) Compounds disclosed in patent application WO0179169: i.e. 2-[(1R)-9-(4-chlorobenzyl)-8-((R)-methyl-sulfinyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl] acetic acid, or a pharmaceutically acceptable salt thereof, or 2-[(1R)-9-(4-chlorobenzyl)-8-((S)-methyl-sulfinyl)-2,3,4,9-tetrahydro-1H-carbazol-1-y] acetic acid, or a pharmaceutically acceptable salt thereof;
- (iii) Compounds disclosed in patent application WO0208186:
-
- and pharmaceutically acceptable salts, hydrates and esters thereof, wherein:
- R1, R2 and R3 are each independently selected from the group consisting of: (1) hydrogen, and (2) Rc,
- R4 and R5 are each independently selected from the group consisting of: (1) H, (2) F, (3) CN, (4) C1-6alkyl, (5) ORa, and (6) S(O)nC1-6alkyl, wherein each of said alkyl group is optionally substituted with halogen, or
- R4 and R5 on the same carbon atom represent an oxo, or
- R4 and R5 on the same carbon atom or on adjacent carbon atoms taken together form a 3- or 4-membered ring containing 0 or 1 heteroatom selected from N, S, or O optionally substituted with one or two groups selected from F, CF3 and CH3;
- R6 is selected from the group consisting of: (1) H, (2) C1-6alkyl optionally substituted with one to six groups independently selected from ORa and halogen, and (3) heterocyclyl optionally substituted with one to four halogen; or
- R5 and R6 attached on adjacent carbon atoms together form a 3- or 4-membered ring containing 0 or 1 heteroatom selected from N, S, or O optionally substituted with one or two groups selected from F, CF3 and CH3;
- X is selected from the group consisting of: C═O, SO2, and C1-4alkyl wherein said alkyl is optionally substituted with one to six halogen;
- Ar is aryl or heteroaryl each optionally substituted with one to four groups independently selected from Rc;
- Q is C1-6alkyl optionally substituted with one to six groups independently selected from: (1) halogen, (2) aryl, (3) heteroaryl, (4) OH, (5) OC1-6alkyl, (6) COOH, (7) CONRaRb, (8) C(O)NSO2R7, (9) tetrazolyl, wherein aryl, heteroaryl and alkyl are each optionally substituted with one to six groups independently selected from halogen, CF3, and COOH; or
- Q and R6 together form a 3- or 4-membered ring optionally containing a heteroatom selected from N, S, and O, and optionally substituted with one or two groups independently selected from: (1) halogen, (2) oxo, (3) ORa, (4) COOH, (5) C(O)NHSO2R7, and (6) tetrazolyl,
- R7 is selected from the group consisting of: (1) C1-6alkyl optionally substituted with one to six halogen, (2) aryl, and (3) heteroaryl, wherein said aryl and heteroaryl are optionally substituted with halogen, OC1-5alkyl, C1-5alkyl and wherein said alkyl is optionally substituted with one to six halogen;
- Ra and Rb are independently selected from hydrogen and C1-6alkyl optionally substituted with one to six halogen;
- Rc is (1) halogen, (2) CN, (3) C1-6alkyl optionally substituted with one to six groups independently selected from halogen, NRaRb, C(O)Ra, C(ORa)RaRb, and ORa, (4) C2-6alkenyl optionally substituted with one to six groups independently selected from halogen and ORa, (5) heterocyclyl, (6) aryl, (7) heteroaryl, (8) C(O)Ra, (9) C(ORa)RaRb (10) C(O)ORa, (11) CONRaRb, (12) OCONRaRb, (13) S(O)nR7, (14) NRaC(O)OC1-6alkyl, wherein alkyl is optionally substituted with one to six halogen and (15) S(O)nNRaRb, wherein heterocyclyl, aryl, heteroaryl are optionally substituted with one to four groups independently selected from halogen; n is 0, 1 or 2.
- (iv) Compounds disclosed in patent application WO03062200:
-
- and pharmaceutically acceptable salts thereof, wherein
- n is 0 or 1; m is 1, 2 or 3; R1 is H, C1-C3 alkyl, halogenated C1-C3 alkyl or cyclopropyl; R2 is 4-chlorophenyl or 2,4,6-trichlorophenyl.
- In particular, a compound of formula IV is (−)-[4-(4-chlorobenzyl)-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid or a pharmaceutically acceptable salt thereof, i.e.:
-
- (v) Compounds disclosed in patent application WO2004103970:
-
- and pharmaceutically acceptable salts thereof, wherein m is 1 or 2, and R1 is C1-C3 alkyl optionally substituted with 1 to 5 halogen atoms.
- Said compound of formula V is in particular selected from the group consisting of: [(3R)-4-[(1S)-1-(4-chlorophenyl)ethyl]-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl] acetic acid and pharmaceutically acceptable salts thereof,
- [(1R)-9-[(1S)-1-(4-chlorophenyl)ethyl]-6-fluoro-8-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl] acetic acid and pharmaceutically acceptable salts thereof,
- [(1R)-9-[(1R)-1-(4-chlorophenyl)-2-fluoroethyl]-6-fluoro-8-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl] acetic acid and pharmaceutically acceptable salts thereof, and
- [(1R)-9-[(1R)-1-(4-chlorophenyl)-2,2-difluoroethyl]-6-fluoro-8-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl] acetic acid and pharmaceutically acceptable salts thereof.
- (vi) [2-(oxazol-2-yl)-5-(4-{4-[(propan-2-yl)oxy]phenylsulfonyl}piperazin-1-yl)phenoxy]acetic acid
-
- or a pharmaceutically acceptable salt thereof, as described in EP2762141. This compound can be synthesized in accordance with a known method, for example, a method as described in WO 2007/037187 or WO 2008/123349.
- Exemplary PTGDR-1 antagonists include, but are not limited to, compounds described as having PGD2 antagonizing activity in PCT Published Applications WO97/00853, WO98/25919, WO01/66520, WO02/094830, WO03/022814, WO03/078409, and WO20041103370; European Patent Applications EP945450, EP944614, and EP 1305286; and U.S. Application Publ. No. 20040220237, 20070244107, and 20080194600, all of which are hereby incorporated by reference in their entirety.
- According other embodiments, the PTGDR-1 antagonist is biological molecule antagonist.
- For instance said PTGDR-1 antagonist is an antibody, preferably monoclonal antibody, or antibody fragment, or aptamer directed against PTGDR-1. Methods of producing polyclonal or monoclonal antibodies are readily available to the skilled person.
- Said PTGDR-1 antagonist may also be an antisense, or interfering RNA inhibiting PTGDR-1 expression.
- In an embodiment said PTGDR-1 antagonist is an anti-sense oligonucleotide, in particular an anti-sense oligonucleotide comprising or consisting of one of the sequence SEQ ID NO:4415 to SEQ ID No:5483, as disclosed in the international patent application published as WO02/081628.
- PTGDR-2 antagonists
- According to an embodiment, said PTGDR-2 antagonist is a small molecule antagonist.
- Numerous PTGDR-1 antagonists have been described in the art.
- In some embodiments, a PTGDR-2 antagonist is selected from the group consisting of:
-
- (i) Compounds disclosed in WO2013088109:
-
- wherein
- R1 is C1-C6 alkyl;
- R2 is halogen;
- R3 is aryl or heteroaryl optionally substituted with one or more substituents selected from halo, OH, CN, R6, COR6, CH2R6, OR6, SR6, SO2R6, or SO2YR6;
- R6 is C1-C6 alkyl, C3-C8 cycloalkyl, heterocyclyl, aryl, or heteroaryl, any of which may optionally be substituted with one or more substituents selected from halo, OH, CN, NO2, C1-C6 alkyl, or O(C1-C6 alkyl); and
- Y is NH or a straight or branched C1-C4 alkylene chain;
- R4 is H or C1-C4 alkyl; and
- R5 is hydrogen, C1-C6 alkyl, aryl, (CH2)mOC(═O)C1-C6 alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R7)2, or CH((CH2)mO(C═O)R8)2;
- m is 1 or 2;
- n is 1-4;
- X is OR7 or N(R7)2;
- R7 is hydrogen or methyl;
- R8 is C1-C,8 alkyl;
- or a pharmaceutically acceptable salt, hydrate, solvate, or complex thereof,
- (ii) cycloalkano(1,2-b)indole-sulfonamides as described in EP0242518B1
-
- wherein R1 is H, fluorine, methyl, methoxy, benzyloxy, or hydroxyl,
- R2 is phenyl which is substituted by fluorine, chlorine, trifluoromethyl, methyl, ethyl, propyl, isopropyl, or methoxy, and
- Y is 0 or 1,
- or pharmaceutically acceptable salts thereof.
- In particular, a compound of formula VIII is selected from the group consisting of:
-
- Ramatroban ((R)-3-[[(4-fluorophenyl)sulphonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid):
-
- or a thermodynamically stable form thereof as described in EP1051398,
- and analogs of Ramatroban, in particular TM30642 (3-(3-[(4-fluoro-benzenesulfonyl)-methyl-amino]1,2,3,4-tetrahydro-carbazol-9-yl (-propionic acid):
-
- TM30643 ([3-(4-fluoro-benzenesulfo-nylamino)-1,2,3,4-tetrahydro-carbazol-9-yl]-acetic acid):
- and
-
- TM30089 (also called CAY10471) (CAS 627865-18-3: 2-[3-[(4-fluorophenyl)sulfonyl-methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]acetic acid):
-
- (iii) OC000549 (5-fluoro-2-methyl-3-(2-quinolinylmethyl)-1H-indole-1-acetic acid)
-
- (iv) Setipiprant
- and
-
- AZD1981 (4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid).
- Additional PTGDR-2 antagonists can be found in the following publications: EP1, 170,594, EP1,435,356 WO2003/066046, WO2003/066047, WO2003/097042, WO2003/097598, WO2003/101961, WO2003/101981, WO2004/007451, WO2004/032848, WO2004/035543, WO20041106302, WO2005/019171, WO2005/054232, WO2005/018529, WO2005/040112, GB2,407,318, WO2005/040114, WO2005/044260, WO2005/095397, WO2005/100321, WO2005/102338, WO2005/123731, WO2006/034419, WO2006/095183, WO2007/107772, WO2008024746, U.S. Pat. No. 7,405,215, each of which is hereby incorporated by reference in its entirety.
- According other embodiments, the PTGDR-2 antagonist is biological molecule antagonist.
- For instance said PTGDR-2 antagonist is an antibody, preferably monoclonal antibody, or antibody fragment, or aptamer directed against PTGDR-2. In an embodiment said PTGDR-2 antagonist is an antibody depleting PTGDR-2 expressing cells such as described in the international patent application WO2014144865.
- Said PTGDR-2 antagonist may also be an antisense, or interfering RNA inhibiting PTGDR-2 expression.
- Dual PTGDR-1/PTGDR-2 antagonists
- As used herein, a dual PTGDR-1/PTGDR-2 antagonist is an antagonist for which the ratio of antagonist activity against PTGDR-1 and PTGDR-2, respectively, is from 1:10 to 10:1, in particular from 1:50 to 50:1, preferably from 1:100 to 100:1, still preferably from 1:250 to 250:1.
- Dual PTGDR-1/PTGDR-2 antagonists that can be used in the frame of the invention include, for instance, the compounds described in patent application WO 2009/085177:
-
- and pharmaceutically acceptable salts thereof,
- wherein R1 is alkyl or cycloalkyl; R2 is halo, alkyl, haloalkyl, alkoxy, haloalkoxy or cycloalkyl; and X is chloro or fluoro.
- Preferably, said compound of formula VI is AMG 853 (2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenyl sulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid):
- AMG 853, as well as a method of preparing this compound, are also described in Liu et al., ACS Med Chem Lett. 2011 Mar. 2; 2(5):326-30.
- However, in an embodiment the dual PTGDR-1/PTGDR-2 antagonists of formula VI are excluded from the scope of the invention.
- Characterisation of the antagonistic activity of a molecule towards PTGDR-1 and/or PTGDR-2 can be performed, for instance, by methods described in Liu et al., ACS Med Chem Lett. 2011 Mar. 2; 2(5):326-30. These methods include:
-
- (i) Determining the molecule's IC50 towards PTGDR-1 and/or PTGDR-2. This can be performed for instance on HEK-293 cells stably expressing human PTGDR-1 or PTGDR-2. To measure binding, detectably labelled PGD2, e.g. [3H]-PGD2, is incubated together with HEK-293 (PTGDR-1 or PTGDR-2) cells in the presence of increasing concentrations of the molecule to be assayed. After incubation, cells are washed, and the amount of labelled PGD2 that remained bound to the cells is measured by an appropriate method (for instance scintillation counting if [3H]-PGD2), and the concentration of compounds required to achieve a 50% inhibition of [3H]-PGD2 binding (the IC50) was determined. The binding buffer contains either 0.5% BSA (buffer binding) or 50% human plasma (plasma binding).
- (ii) Determining the molecule's affinity for PTGDR-1. This can be performed for instance on whole blood drawn into acid-citrate-dextrose vacutainer tubes, treated with test molecule or DMSO, and then stimulated with a dose response of PGD2. Cells are then lysed, and cAMP is measured using a competitive ELISA. Comparison of the dose response to PGD2 in samples containing DMSO only and samples containing with test molecule is used in determining Kb using the Schild equation (Schild HO. PA2, a new scale for the measurement of drug antagonism. Brit J Pharmacol 1947; 2:189-206).
- (i) Determining the molecule's affinity for PTGDR-2. This can be performed for instance on whole blood drawn into acid-citrate-dextrose anticoagulated tubes, treated with test molecule or DMSO, and then stimulated with a dose response of PGD2. Fluorochrome conjugated antibodies are used to label PTGDR-2 positive granulocytes, and PTGDR-2 receptor internalization is monitored by flow cytometry. The Kb is determined using the Schild equation.
- Mono- or Combination Treatment
- Since both PTGDRs can synergize, antagonizing both PTGDR-1 and PTGDR-2 is an advantageous therapeutic modality for treating and/or preventing lupus. Furthermore, this should avoid any risk of potentiation of PGD2 effect on basophils and other cells via the unblocked PTGDR, if only one of the two PGD2 receptors is targeted.
- According to an embodiment, said PTGDR-1 (or PTGDR-2 antagonist) is a dual PTGDR-1/PTGDR-2 antagonist.
- According to another embodiment, said PTGDR-1 antagonist is not a dual PTGDR-1/PTGDR-2 antagonist. In said embodiment, the PTGDR-1 antagonist is used either as the sole active ingredient (mono-treatment) for the prevention and/or treatment of SLE, or in combination with at least a PTGDR-2 antagonist (which is neither a dual PTGDR-1/PTGDR-2 antagonist) for the prevention and/or treatment of SLE.
- According to another embodiment, said PTGDR-2 antagonist is not a dual PTGDR-1/PTGDR-2 antagonist. In said embodiment, the PTGDR-2 antagonist is used either as the sole active ingredient (mono-treatment) for the prevention and/or treatment of SLE, or in combination with at least a PTGDR-1 antagonist (which is neither a dual PTGDR-1/PTGDR-2 antagonist) for the prevention and/or treatment of SLE.
- Additionally, in an embodiment, the PTGDR-1 antagonist, the PTGDR-2 antagonist, or the combination of PTGDR-1 antagonist and PTGDR-2 antagonist, is used in combination with any other standard therapy for the treatment of lupus. Therapeutics useful for the treatment of lupus include, but are not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), hydroxychloroquine, corticosteroids, cyckophosphamide, azthioprine, methotrexate, mycophenolate mofetil (MMF) (CelleCept®), belimumab, dehydroepiandrosterone, and rituximab.
- The PTGDR-1 and/or PTGDR-2 antagonist(s), and optionally further the standard therapeutic for the treatment of lupus, are formulated into one or more pharmaceutical composition(s) comprising said PTGDR-1 and/or PTGDR-2 antagonist(s), and optionally further the standard therapeutic for the treatment of lupus, and at least one carrier, excipient or diluent.
- “Pharmaceutically” or “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier, excipient or diluent refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- Pharmaceutically acceptable carriers and excipient that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminium stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyicellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- As appreciated by skilled artisans, the pharmaceutical composition is suitably formulated to be compatible with the intended route of administration. Examples of suitable routes of administration include topical route, oral route, intranasal route, intraocular route, parenteral route, including for instance intramuscular, subcutaneous, intravenous, intraperitoneal or local injections. The oral route can be used, provided that the composition is in a form suitable for oral administration, able to protect the active principle from the gastric and intestinal enzymes.
- Preferably, the pharmaceutical composition contains carriers that are pharmaceutically acceptable for an injectable formulation. They may in particular be sterile, isotonic, saline solutions (monosodium phosphate, disodium phosphate, sodium chloride, potassium chloride, calcium chloride or magnesium chloride etc., or mixtures of such salts), or dry, in particular lyophilized, compositions which by means of the addition, as appropriate, of sterilized water or physiological saline, can form injectable solutes.
- For combined therapy, (i) the PTGDR-1 antagonist and PTGDR-2 antagonist, (ii) the PTGDR-1 antagonist and the standard therapeutic for the treatment of lupus, (iii) the PTGDR-2 antagonist and the standard therapeutic for the treatment of lupus, or (iv) the PTGDR-1 antagonist, PTGDR-2 antagonist and the standard therapeutic for the treatment of lupus, are formulated in a single pharmaceutical composition, or said PTGDR-1 antagonist, PTGDR-2 antagonist, and standard therapeutic for the treatment of lupus, are formulated in separate pharmaceutical compositions for simultaneous use, separate use, or use spread over time.
- Thus the invention also provides for a pharmaceutical composition comprising a PTGDR-1 antagonist and a PTGDR-2 antagonist; or a dual PTGDR-1/PTGDR-2 antagonist; a PTGDR-1 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-1 antagonist, a PTGDR-2 antagonist, and a standard therapeutic for the treatment of lupus; or a dual PTGDR-1/PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus, for use in a method for preventing and/or treating SLE.
- Accordingly, it is provided a method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist and a PTGDR-2 antagonist, or a dual PTGDR-1/PTGDR-2 antagonist. In an embodiment of said method a standard therapeutic for the treatment of lupus is further step administered with the PTGDR-1 antagonist and PTGDR-2 antagonist, or with the dual PTGDR-1/PTGDR-2 antagonist. A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist or a PTGDR-2 antagonist, and with a standard therapeutic for the treatment of lupus, also makes part of the invention.
- The invention also relates to PTGDR-1 antagonist and a PTGDR-2 antagonist; or a dual PTGDR-1/PTGDR-2 antagonist; a PTGDR-1 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus; a PTGDR-1 antagonist, a PTGDR-2 antagonist, and a standard therapeutic for the treatment of lupus; or a dual PTGDR-1/PTGDR-2 antagonist and a standard therapeutic for the treatment of lupus, for use as a combined preparation for simultaneous use, separate use, or use spread over time, in a method for preventing and/or treating SLE.
- The methods of preventing and/or treating SLE according to the invention preferably use an effective amount of PTGDR-1 and/or PTGDR-2 antagonist and/or standard therapeutic for the treatment of lupus.
- The expression “effective amount” is intended to mean an amount sufficient to prevent and/or treat a given disease. It will be appreciated that this amount will vary with the effectiveness of therapeutic agent(s) employed, with the nature of any carrier used, with the seriousness of the disease and the age of the patient. The determination of appropriate amounts for any given composition is within the skill in the art, through standard series of tests designed to assess appropriate therapeutic levels.
- According to invention the PTGDR-1 antagonist and/or PTGDR-2 antagonist prevent(s) basophil homing to secondary lymphoid organs.
- In the frame of the invention, the PTGDR-1 antagonist and/or PTGDR-2 antagonist prevents, limits the extent or reduces the increase in autoantibody titers and/or the occurrence of SLE flares. Alternatively or furthermore, the PTGDR-1 antagonist and/or PTGDR-2 antagonist also prevents, limits the extent or reduces the occurrence organ damages, in particular to kidneys, heart, lungs, and brain. In an embodiment, the PTGDR-1 antagonist and/or PTGDR-2 antagonist prevents, limits the extent or reduces the occurrence of lupus nephritis.
- The invention will be further illustrated in view of the following figures and examples.
-
FIG. 1 . Human blood basophil gating strategy and activation status In function of SLE disease activity. -
- (a) Flow cytometric analysis of CD203c levels on blood basophils from subjects with inactive, mild or active SLE (n=60/40/82, respectively) compared to controls (CT, n=100). (b) Flow cytometric analysis of CD62L levels on blood basophils from subjects with inactive, mild or active SLE (n=43/33/66, respectively) compared to controls (CT, n=90). (c) Flow cytometric analysis of CD63 levels on blood basophils from subjects with inactive, mild or active SLE (n=14/6/12, respectively) compared to controls (CT, n=12). (a-c) Data are normalized to controls' mean and expressed in arbitrary units as means+s.e.m. Statistical analyses were by Mann-Whitney tests. NS: not significant, *: P<0.05, **: P<0.01, ***: P<0.001.
-
FIG. 2 . Basopenia and basophil activation status correlate with disease activity and are specific for lupus nephritis among other active renal diseases. -
- (a) Blood basophils per μL as determined by flow cytometry from healthy controls (CT) and subjects with inactive, mild or active SLE (n=87/58/38/84, respectively) as defined in the online methods. (b) Spearman correlation between blood basophil numbers and SLEDAI (r=−0.3629, p<0.0001) shown on a linear scale. (c) Proportion of blood HLA-DR+ basophils as determined by flow cytometry healthy controls (CT) and subjects with inactive, mild or active SLE (n=96/60/40/84, respectively). (d) Receiver-Operating Characteristic (ROC) analysis of the proportion of HLA-DR+ basophils in SLE patients (n=184) versus controls (n=97) (thick line, AUC=0.9091) and of dsDNA-specific IgG titers in SLE patients (n=123) versus controls (n=39) (dotted line, AUC=0.8384). (e) Blood basophils per μL as in (a) from subjects with the following active renal diseases: IgA-N: IgA nephropathy; HSP: Henoch-Schönlein purpura nephropathy; DN: Diabetic Nephropathy; MN: membranous nephropathy; OGN: Other glomerular nephropathies; NGKD: Non-Glomerular Kidney Diseases; aLN: active Lupus Nephritis; compared to healthy controls (n=40/20/39/22/42/46/81/87, respectively). (f) Proportion of blood HLA-DR+ basophils in patients with active renal diseases as in (e) (n=40/20/39/21/51/47/77, respectively) compared to controls (n=96). (a,c,e,f) Data are expressed as means+s.e.m. Statistical analyses were by Mann-Whitney tests. Comparison to healthy controls' median is shown above each bar and to the corresponding bars when indicated. NS: not significant, *: P<0.05, **: P<0.01, ***: P<0.001, ****: P<0.0001.
-
FIG. 3 . PGD2/PTGDRs and CXCL12/CXCR4 axes contribute to SLE patient specific basophil phenotype -
- (a) Flow cytometric analysis of PTGDR-2 (CRTH2) levels on blood basophils from healthy controls (CT) and subjects with inactive, mild or active SLE (n=71/48/31/60, respectively). (b) 11β-prostaglandin F2α (11β-PGF2α) levels in plasma from controls and individuals with inactive, mild or active SLE (n=29/31/19/37, respectively) as measured by EIA. (c) Blood basophils per μl of blood in subjects with SLE classified on the basis of low (n=51) or high (n=34) 11β-PGF2α plasma levels (titer below or above CT titer mean+2 standard deviations, respectively). (d) Flow cytometric analysis of CXCR4 levels on blood basophils from CT and subjects with inactive, mild or active SLE (n=66/32/20/51, respectively). (e) CXCL12 levels in plasma from controls and individuals with inactive, mild or active SLE (n=63/43/29/59, respectively) as measured by ELISA. (f) Flow cytometric analysis of the levels of CD164 on blood basophils from CT and subjects with inactive, mild or active SLE (n=33/15/7/26, respectively). (a,d,f) Data are normalized to the mean of CT values and expressed in arbitrary units. (a-f), Statistical analyses were by Mann-Whitney tests. Comparison to healthy controls' median is shown above each bar and to the corresponding bars when indicated. Data are expressed as means+s.e.m. NS: not significant, *: P<0.05, **: P<0.01, ***: P<0.001, ****: P<0.0001.
-
FIG. 4 . Associations between plasma 11β-PGF2α & CXCL12 titers, basophil CXCR4 & CD164 expression levels and lupus specific basopenia -
- (a) Spearman correlation between blood basophil number per mL of blood and 11β-PGF2α plasma levels (r=−0.2585, P=0.0169, n=85) shown on a logarithmic scale. (b) Spearman correlation between blood basophil number per mL of blood and relative CXCR4 levels on basophils (as defined in
FIG. 2 d ) (r=−0.4692, P<0.0001, n=101) shown on a logarithmic scale. (c) Blood basophils per μl of blood in subjects with active SLE classified on the basis of low or high CXCL12 plasma levels (titer below or above control titer mean+2 standard deviations, respectively). Data are expressed as means+s.e.m. Statistical analysis was by Mann-Whitney test. *: P<0.05. (d) Spearman correlation between blood basophil number per mL of blood and relative CD164 levels on basophils (as defined inFIG. 2 f ) (r=−0.4165, P-0.0029, n=49) shown on a logarithmic scale.
- (a) Spearman correlation between blood basophil number per mL of blood and 11β-PGF2α plasma levels (r=−0.2585, P=0.0169, n=85) shown on a logarithmic scale. (b) Spearman correlation between blood basophil number per mL of blood and relative CXCR4 levels on basophils (as defined in
-
FIG. 5 . CXCR4-mediated basophil migration ex vivo and in vivo is enhanced by PGD2 -
- (a) Migration assays of human blood basophils from healthy controls (CT, n=6) and SLE patients (n=6) towards a CXCL12 gradient. (b) Migration assays of human blood basophils towards IL-3, CCL3, CCL5, CXCL2 and PGD2 gradients from healthy controls (Controls, n=8/4/3/4/7, respectively) and from SLE patients (SLE, n=6/3/6/3/5, respectively). (c) Relative dsDNA-specific IgE levels in plasma from inactive, mild or active SLE individuals (n=41/29/51, respectively) normalized to the control values mean (n=38) as measured by ELISA. (a-c) Statistical analyses were by Mann-Whitney tests compared to CT. (d) CXCR4 expression levels on blood basophils after 18 hours of incubation without (−) or with (+) PGD2, mouse anti-human IgE or IL-3 was assessed by flow cytometry. (e) Migration assays of human blood basophils stimulated as in (d) towards a CXCL12 gradient. (d,e) Statistical analyses were by paired Student t test. (f) Expression level variation of the indicated basophil markers between peritoneal and blood basophils from patients undergoing peritoneal dialysis and being treated for non-sterile peritonitis (n=6) were assessed by flow cytometry. Statistical analysis was by one sample t test compared to a 0 theoretical value. (a,b,e) Corrected migration as described in the methods. (a-f) Data are expressed as means±s.e.m. NS: not significant, #: P=0.06, *: P<0.05, **: P<0.01, ***: P<0.001, ****: P<0.0001.
-
FIG. 6 . Suboptimal IgE-mediated basophil activation leads to increased PTGDR-2 expression on human basophils. -
- PTGDR-2 (CRTH2) expression levels (as defined in online methods) on blood basophils from healthy donors after 18 hours of incubation without (−) or with (+) PGD2, mouse anti-human IgE or IL-3. Statistical analyses were by paired Student t test.
-
FIG. 7 . PGD2 Is sufficient to enhance the CXCL12-dependent basophil homing to SLOs occurring In lupus-prone mice -
- (a) Ex vivo migration of basophils from whole WT or Lyn−/− splenocytes to CXCL12. (b) CXCR4 expression levels on basophils from the indicated compartments in aged WT (n=16) and Lyn−/− (n=14) animals. Data are normalized to the mean CXCR4 expression level of WT blood basophils. Statistical analyses placed directly above each bar compared the value for one given compartment to the blood compartment of the corresponding genotype. Statistical analyses between both genotypes for each compartment are also indicated. (c) Basophil number per peritoneum in young WT mice 24 hours after intraperitoneal (ip) injection of PBS or CXCL12 and compared to steady state (−) values (n =13/15/5, respectively). (d) CXCR4 expression levels on basophils from mesenteric lymph nodes (mLN) of young Lyn−/− mice 24 hours after PBS or PGD2 ip injection normalized to PBS injected mice values' mean. (e) Basophil number in mLN of young Lyn−/− mice 24 hours after ip injection of the indicated compound(s). (f) CXCR4 expression levels on spleen basophils from 15 weeks old WT mice incubated ex vivo for 24 hours with the indicated compound and normalized to the control values' mean. (a-f) Data are expressed as means±s.e.m. Basophils number and CXCR4 expression were assessed by flow cytometry. Statistical analyses were by unpaired t test with Welch's correction (a-e) and by paired Student t test (f). NS: not significant, #: PL0.058, *: P<0.05, **: P<0.01, ***: P<0.001, ****: P<0.0001.
-
FIG. 8 . CXCL12 or PGD2 Ip Injection In mice Induce a CXCR4-dependent basophil accumulation In SLOs and peritoneum. -
- (a) Proportion of basophil (x103) among living CD45+ cells in mesenteric lymph node (mLN) of young WT mice 24 hours after intraperitoneal (ip) injection of PBS (n=13) or CXCL12 (n=15) and compared to steady state (−) values (n=5). (b) Basophil number in spleen of young Lyn−/− mice 24 hours after ip injection of the indicated compound(s). (c) Basophil number in peritoneum of Lyn−/− mice 24 hours after ip injection of the indicated compound(s). Data are expressed as means±s.e.m. Statistical analyses were by unpaired Student t test with Welch's correction. NS: not significant, *: P<0.05, **: P<0.01, ***: P<0.001.
-
FIG. 9 : cAMP and PTGDRs specific agonist effects on CXCR4 expression by mouse spleen basophils ex vivo. -
- (a-b) Relative CXCR4 expression levels on basophils (defined as CD19− TCRβ− CD3− CD49b+ FcεRlα+ CD123+ CD45lo) and T cells (defined as CD45+CD3+TCRβ+ cells) in splenocytes incubated 4 hours without (−) or with the indicated concentration of N6,2′-O-dibutyryl-
adenosine 3′:5′-cyclic monophosphate (db-cAMP) or 1 μM PGD2 as determined by flow cytometry. Statistical analyses were by paired Student t tests. NS: not significant, *: P<0.05, **: P<0.01, ***: P<0.001. (c) Relative CXCR4 expression levels on spleen basophils (defined as in (a)) incubated 4 hours without (0) or with the indicated concentration (nM) of the indicated compound(s). DK-PGD2: 13,14-dihydro-15-keto-PGD2 (PTGDR-2 specific agonist); BW245c: 3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxo-(R*,S*)-(±)-4-imidazolineheptanioc acid (PTGDR-1 specific agonist) as determined by flow cytometry. Statistical analysis was by two-ways ANOVA followed by a Tukey's multiple comparisons test. (a-c) Data are normalized to control value mean (per group, n=4 to 8). Data are expressed as mean+s.e.m. All experiments were realized with splenocytes from 8-12 weeks old WT mice.
- (a-b) Relative CXCR4 expression levels on basophils (defined as CD19− TCRβ− CD3− CD49b+ FcεRlα+ CD123+ CD45lo) and T cells (defined as CD45+CD3+TCRβ+ cells) in splenocytes incubated 4 hours without (−) or with the indicated concentration of N6,2′-O-dibutyryl-
-
FIG. 10 . Blockade of basophil accumulation In SLOs dampens lupus-like disease activity -
- (a,b) Proportion of basophils (CD19− TCRβ− CD49b+ FcεRlα+ CD123+ CD45lo) among singlets living CD45+ cells in mesenteric (a) and other (cervical, brachial and inguinal) lymph nodes (b) from 10 to 12 weeks-old Lyn−/− mice injected over ten days with PBS (open circles) or PGD2 alone (open squares), and PGD2 injected and basophil depleted (MAR-1) (open diamonds) or not (IgG) (open triangles) as described in the methods. (c) IA-IE expression levels on LN basophils from mice as in (b). NA: not applicable. (d,e) Proportion of short lived plasma cells CD19+ CD138+ among singlets living CD45+ cells in spleen (d) and lymph nodes (e) in the same mice as in (b). (f) Representative immunofluorescence staining for C3 and IgG deposits in kidneys from mice as indicated in (b) (scale bar=1 mm) and their corresponding quantifications in PBS (n=3), PGD2 (n=4), PGD2+control IgG (n=3) and PGD2+MAR-1 (n=3) injected mice. (g) Fold increase in urine albumin/creatinine ratio before and after PBS or
PGD 2 10 days-long treatment. (a-e) Basophil, plasma cell numbers and IA-IE expression levels were assessed by flow cytometry. (a-g) Data are expressed as means±s.e.m. Statistical analyses were by unpaired student t tests. #: P=0.0571, *: P<0.05, **: P<0.01, ***: P<0.001, ****: P<0.0001. One representative out of three independent experiments is shown.
- (a,b) Proportion of basophils (CD19− TCRβ− CD49b+ FcεRlα+ CD123+ CD45lo) among singlets living CD45+ cells in mesenteric (a) and other (cervical, brachial and inguinal) lymph nodes (b) from 10 to 12 weeks-old Lyn−/− mice injected over ten days with PBS (open circles) or PGD2 alone (open squares), and PGD2 injected and basophil depleted (MAR-1) (open diamonds) or not (IgG) (open triangles) as described in the methods. (c) IA-IE expression levels on LN basophils from mice as in (b). NA: not applicable. (d,e) Proportion of short lived plasma cells CD19+ CD138+ among singlets living CD45+ cells in spleen (d) and lymph nodes (e) in the same mice as in (b). (f) Representative immunofluorescence staining for C3 and IgG deposits in kidneys from mice as indicated in (b) (scale bar=1 mm) and their corresponding quantifications in PBS (n=3), PGD2 (n=4), PGD2+control IgG (n=3) and PGD2+MAR-1 (n=3) injected mice. (g) Fold increase in urine albumin/creatinine ratio before and after PBS or
-
FIG. 11 . Blockade of basophil accumulation in SLOs dampens lupus-like disease activity -
- Quantifications of immunofluorescence staining for C3 and IgG deposits in kidneys from aged Lyn−/− mice treated (n=8) or not (vehicle, n=9) with PTGDR-1 and PTGDR-2 antagonists for ten days.
-
FIG. 12 . Targeting PTGDRs blocks CXCR4-mediated basophil accumulation In SLOs and reduces the lupus-like disease activity. -
- (a-h) Comparisons between aged wild-type (WT) and Lyn−/− mice treated or not (vehicle) for 10 days with PTGDR-1 and PTGDR-2 antagonists as described in the online methods. (a,b,c) Flow cytometric analysis of basophils among living CD45+ cells in lymph nodes (cervical, axillar, inguinal and mesenteric) (a) and spleen (b). (c) CXCR4 expression levels on spleen basophils. (d) Proportion of short lived plasma cells CD19+CD138+ among living CD45+ cells in lymph nodes as in (a) was determined by flow cytometry. (e) Optical density (O.D.) values at 450 nm of dsDNA-specific IgG in plasma from the indicated mice as measured by ELISA (x103). (f) Total IgE levels as measured by ELISA in plasma from the indicated mice. (g,h) IL-4 (g) and IL-1β (h) concentration in pg per mg of total kidney protein extract from the indicated mice as measured by ELISA. (a-h) WT vehicle, n=5; WT treated, n=4; Lyn−/− vehicle, n=8; Lyn−/− treated, n=8. Data are expressed as mean+s.e.m. Statistical analyses were by unpaired Student t tests. NS: not significant, *: P<0.05, **: P<0.01.
-
FIG. 13 . Treatment with PTGDRs antagonists reduces specifically basophil accumulation in SLOs leading to reduced short-lived plasma cell number and serum ANA titers. -
- (a-d) Comparisons between aged wild-type (WT) and Lyn−/− mice treated or not (vehicle) with PTGDR-1 and PTGDR-2 antagonists for ten days. (a,b) Flow cytometric analysis of basophil proportion among CD45+ bone marrow (BM) cells (a) and blood leukocytes (b). (c) Flow cytometric analysis of short lived plasma cells CD19+CD138+ among living CD45+ cells. (d) Anti-nuclear antibodies (ANA) levels as measured by ELISA in plasma from the indicated mice. (a-d) WT vehicle, n=5; WT treated, n=4; Lyn−/− vehicle, n=8; Lyn−/− treated, n=8. Data are expressed as means+s.e.m. (a-c) Statistical analyses were by unpaired Student t test. (d) Statistical analysis was by Mann-Whitney test. NS: not significant, *: P<0.05, **: P<0.01.
-
FIG. 14 . Graphical abstract -
- In systemic lupus erythematosus (SLE), a loss of self-tolerance induces the expansion of autoreactive (AR) T and B cells. Autoreactive plasma cells secrete autoreactive antibodies which will bind self-antigens of nuclear origin and complement factors to form circulating immune complexes (CIC). The deposition of these CIC or autoreactive antibodies in target organs is associated with local lesions, inflammation (and PGD2 production), and organ damages. Healthy basophils can get activated by the binding of CIC to Fc receptors (FcεRI and FcγRs) to express more prostaglandin D2 (PGD2) receptors (PTGDRs) and activation markers such as CD203c. As chronic inflammation settles, so does the secretion of various inflammatory mediators in blood, including PGD2. PGD2 is sufficient to induce PGD2 production by circulating basophils themselves leading to an autocrine effect of PGD2. This leads to an increased surface expression of CXCR4 and enable basophil sensitivity to CXCL12 gradients. As a result, basophils are more eager to migrate to SLOs, which are known to secrete more CXCL12 during lupus pathogenesis. There, basophils support autoreactive T and B cells through their expression of activating molecules such as mBAFF, MHC-II or the secretion of various cytokines such as IL-4 and IL-6. Moreover, basophils can promote autoreactive antibody production and IgE class switching of B cells. As CIC and autoreactive IgE titers increase, so will targeted organ inflammation, PGD2 and CXCL12 titers and basophils homing to SLOs. It is assumed that basophils drive an amplification loop of the disease and blocking their recruitment to SLOs would prevent rise in autoantibody titers and consequent flares.
- Mice.
- C57BL/6J wild-type (WT) mice were purchased from Charles River Laboratories (L'Arbresle, France) and Lyn−/− mice on a pure C57BL/6 background were bred in our animal facility. For lupus-like disease studies, mice were aged for a minimum of 40 weeks before treatment and analysis. For other ex vivo or in vivo analysis, young mice were between 8 and 12 weeks old, unless otherwise specified. Mice were maintained in specific pathogen-free conditions, used in accordance with French and European guidelines and approved by local ethical committee and by the Department of Research of the French government under the animal study proposal 02484.01.
- Patients.
- Blood samples were collected from adult subjects enrolled in a prospective long term study of systemic lupus erythematosus (SLE) and chronic renal diseases. The study was approved by the Comité Régional de Protection des Personnes (CRPP, Paris, France) under the reference ID-RCB 2014-A00809-38. Diagnostics of inpatients were not known by the investigators at the time of sample processing and flow cytometry analysis. SLE samples were obtained from in- and outpatients and clinical data were harvested after approval by the Comission Nationale de l'Informatique et des Libertés (CNIL). All SLE subjects fulfilled the American College of Rheumatology classification criteria for SLE. SLE and healthy control (HC) donor characteristics are shown in Table 1 (below). Lupus activity was assessed by SELENA-SLEDAI (Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Disease Activity Index) scores. Based on the SLEDAI score, lupus activity was classified as inactive (0-1), mild (2-4) and active (>4). All samples were collected in heparin blood collection tubes and processed within 4 hours. A written informed consent was obtained from all subjects. Active lupus nephritis subjects were defined by histologically active classes Ill or IV+/−V nephritis, in accordance with the ISN/RPS classification (Weening, J. J., et al., J. Am. Soc. Nephrol. 15, 241-250 (2004)).
- Antibodies and Flow Cytometry
- All antibodies were from commercial sources. Flow cytometry acquisition was done with a LSRII Fortessa using DIVA software (BD Biosciences). Blood sample processing procedure was as previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). All data relative to marker expression levels are expressed as the ratio between the geometric mean fluorescence intensity (Geo MFI) of the indicated marker on the cells of interest and the Geo MFI of the corresponding isotype control. Data were normalized or not as indicated in figure legends. Data analysis was realized with FlowJo v.X.0.7 (Treestar).
- Chemokines, Cytokines, 11P-PGF2 and Immunoglobulin Measurement Assays
- All commercial assays were performed according to the manufacturer instructions. 11β-Prostaglandin F2α enzyme immunoassay (EIA) kits were from Cayman Chemicals (Ann Arbor, MI). Mouse ANA enzyme linked immunosorbent assay (ELISA) kits were from ADI (San Antonio, TX). Human and mice CXCL12 ELISA kits were from R&D Systems (Minneapolis, MN). Assessment of cytokine content in the kidney was previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). Mouse IL4 and IL1β ELISA kits were from BioLegend (San Diego, CA). Mouse IgE Quantification ELISA kits were from Bethyl Laboratories (Montgomery, TX). Human and mouse anti-dsDNA IgG and IgE were quantified as previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). Absorbance was assessed by an
Infinite 200 Pro plate reader (TECAN, Mannedorf, Switzerland). - Human Basophil Purification and Enrichment.
- Human basophils were purified to >95% by negative selection with the Human Basophils Enrichment kit (Stemcell Technologies, Grenoble, France) for culture, stimulation and chemotaxis experiments. In some chemotaxis experiments, human basophils were enriched to 3-5% by negative selection with the Human PE positive selection kit (Stemcell Technologies) by using a cocktail of PE-conjugated anti-CD3, CD19 and CD89 (BioLegend). These kits were used following manufacturer instructions.
- Imaging Flow Cytometry
- Basophils were enriched to 3-5% as described above and frozen at −80° C. in 90
% FCS 10% dimethyl sulfoxide until enough samples were collected. Thawed cells were stained, fixed (IC fixation buffer, eBioscience) and permeabilized (Wash Perm Buffer, BioLegend) following the manufacturers' instructions. Anti-human CXCR4 or its isotype (BioLegend) were used for intracellular staining. DAPI was added prior to cytometry analysis. Basophils were gated as Singlets cells/Focus high/DAPI high/PE− CD123+ FcεRIα+ CD303−. CXCR4 expression was determined for each basophil as the ratio of the geometric mean of their CXCR4 intensity on the mean basophil CXCR4 FMO (Fluorescence Minus One) intensity. Internalization scores were determined using Fc□RI□ staining as a membrane marker and CXCR4 staining as the probe. For each sample, externalization score corresponds to [1−internalization score]. All analyses were performed using the ImageStream X Mark II imaging flow cytometer and the IDEAS v6 software (AMNIS). - Basophil Culture and Stimulation
- Human basophils and mouse splenocytes were cultured in culture medium (RPMI 1640 with Glutamax and 20 mM HEPES, 1 mM Na-pyruvate, non-essential amino acids 1X (all from Life Technologies, Saint-Aubin, France), 100 μg/ml streptomycin and 100 U/ml penicillin (GE Healthcare, Vélizy, France) and 37.5 μM β-mercaptoethanol (Sigma-Aldrich, MO)) supplemented with 20% heat-inactivated fetal calf serum at 37° C. and 5% CO2. 18 hours-long stimulation prior to migration assays were done in culture medium at 1×106 cells per mL by adding 1 nM of IL-3 (Peprotech), 1 μM of prostaglandin D2 (PGD2), 1 μM of the PTGDR-1 specific agonist BW245c, 1 μM of the PTGDR-2 specific agonist 13,14-dihydro-15-keto Prostaglandin D2 (DK-PGD2) (all from Cayman chemicals) or 5 ng/mL of anti-IgE (mouse anti-human IgE or rat anti-mouse IgE, both from Thermo Scientific). All cells were washed twice before any migration assay. Control conditions were always with the same vehicle concentration as stimulated conditions.
- For CXCR4 overexpression modulation by PTGDRs antagonists, PGD2 and H-PGDS inhibitor, purified basophils were resuspended in RPMI containing 0.1% BSA+/− the following compounds: vehicle (ethanol 0.1%), 1 μM PTGDR-1 antagonist Laropiprant, 1 μM PTGDR-2 antagonist CAY10471, 1 or 10 μM PGD2, and 1 μM of Prostaglandin D Synthase (hematopoietic-type) Inhibitor I (catalog #16256) (all from Cayman Chemical). Cells were incubated for 4 hours at 37° C. and 5% CO2 and surface expression of the indicated markers were assessed by flow cytometry.
- Basophil Migration and Apoptosis Assays
- Migration assays were performed in culture medium supplemented with 0.1% bovine serum albumin (BSA, Sigma-Aldrich) in
Transwell 5 μm polycarbonate permeable support 6.5 mm inserts (Corning, New York, NY) for 3 hours at 37° C. and 5% CO2 with 1×105 purified basophils or 2×105 enriched basophils at 1×106 cells per mL. Purified or enriched basophils from the upper and bottom chambers were counted at the end of the assay. Basophil content and phenotype was determined by flow cytometry by analyzing more than 100 basophils. Purification or enrichment of human basophils didn't show any difference in the measured migration for all tested chemokines. Migration was defined as the ratio between the number of basophils in the bottom chamber and the number of basophils in the upper plus the bottom chambers. Spontaneous migration was defined as the migration observed without any chemokine in the bottom chamber. Corrected migration was defined as the difference between specific and spontaneous migration. For migration assays the following concentrations (known to be optimal) were used for each compound: Human IL-3: 300 μM (Peprotech), human CCL3, CCL5, and CXCL12: 50 nM; CXCL2 (all from BioLegend) and PGD2 (Cayman chemicals): 100 nM. Migration to human CCL3, CCL5, CXCL2, and PGD2 was done in the presence of IL-3 at 300 μM in both chambers. Migration with IL-3 represents chemokinetism: IL-3 was added in both chambers to the same concentration and compared to the spontaneous migration observed without IL-3. Effects of 24 hours incubation with IL-3 or PGD2 (as described above) on basophil apoptosis were estimated by using the FITC Annexin V Apoptosis Detection Kit from BD Biosciences and used accordingly to manufacturer's instructions. - In Vivo Experiments
- For CXCL12-induced basophil in vivo migration assays, 200 μL of PBS containing 100 ng of murine CXCL12 or PBS alone were injected intraperitoneally (ip) in 8-12 weeks old WT mice. For PGD2-induced basophil in vivo migration assays, 100 μL of PBS (with 2 μL of ethanol) alone, or PBS ±20 nmoles of PGD2 ±200 μg of AMD3100 (all from Cayman Chemicals) were injected ip in 8-12 weeks old Lyn−/− mice. In all cases, 24 hours later, mice were euthanized and peritoneal lavage, blood, mesenteric lymph nodes and spleen were collected and prepared for FACS analysis as previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). For acceleration of disease development by PGD2 injections, 12 weeks old Lyn−/− mice were injected ip with 20 nmoles of PGD2 or vehicle in PBS, every two days for 10 days, for a total of 6 injections. Mice were analyzed the day following the last injection. For treatment with PTGDRs antagonists, aged WT and Lyn−/− mice were treated by oral doses of 5 mg/kg of Laropiprant and CAY10471 (Cayman chemicals) or equivalent dose of ethanol (vehicle) in tap water twice a day for ten days. Then, mice were euthanized and blood, plasma, spleen, bone marrow, kidneys and lymph nodes (cervical, brachial, inguinal and mesenteric) were analyzed as previously described (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). The treatment didn't affect weight and cell numbers in the different organs. Cell viability was assessed by the utilization of Ghost Dye Violet 510 (Tonbo, San Diego, CA).
- Analysis of Glomerular Deposition of IgG and C3, and Kidney Function.
- Kidney preparation for immunofluorescence analysis of C3 and IgG deposits was as previously described (Charles, N et al. Nat. Med., 2010, 16, 701-707, 2159). Quantification of C3 and IgG deposits was realized by using ImageJ software (v1.49p, NIH, USA). A minimum of 20 glomeruli was quantified per kidney. For assessment of kidney function the albumin/creatinine ratio (ACR) was determined. Urine was collected from each mouse before and after treatment. The albumin concentration was measured with a mouse albumin ELISA (Bethyl laboratories, Montgomery, TX). A creatinine assay (R&D systems, Minneapolis, MN) was used to determine urine creatinine concentrations. Results are expressed as a fold increase corresponding to the ratio of the ACR after/before treatment.
- Statistical Analysis.
- Distribution was assessed with D'Agostino-Pearson omnibus normality test or Kolmogorov-Smirnov test, depending on sample size, to perform appropriate analyses. When more than 2 groups were compared, one-way analysis of variance (ANOVA) tests were conducted before the indicated post-tests when significance (p<0.05) was reached. All tests run were two-tailed. Statistics were performed with GraphPad Prism V5 and V6 (GraphPad) and with STATA 12 (Statacorp) softwares.
- Specific SLE and Lupus Nephritis Basophil Phenotype
- On a cohort of individuals with SLE (n=188, Table 1), we first validated that SLE subject basophils had an activated phenotype as shown by increased CD203c (a basophil activation marker) and CD62L (L-selectin, involved in leukocyte rolling) expressions as compared to healthy control (HC) ones (n=98,
FIG. 1 a-b , Table 1) (Charles, N. et al., Nat. Med. 16, 701-707 (2010)). - However, SLE basophils did not display a degranulated phenotype (as measured by their CD63 expression level,
FIG. 1 c ). Basopenia appeared to be a good marker of disease correlating with SLE disease activity index (SLEDAI, American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response, C. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 50, 3418-3426 (2004)) (Spearman r coefficient=−0.3629, P<0.0001) (FIG. 2 a,b ), whereas proportion of HLA-DR positive basophils was better (Receiver Operating Characteristic (ROC) Area Under Curve (AUC)=0.9091) than anti-dsDNA IgG (ROC AUC=0.8384) to discriminate SLE subjects from healthy control (HC) (ROC AUC comparison by DeLong method (DeLong, E. R. et al., Biometrics 44, 837-845 (1988)): P=0.03) (FIG. 2 c,d ). Moreover, basopenia and high proportion of HLA-DR+ basophils were specific markers for active lupus nephritis when compared to other active renal diseases (FIG. 2 e,f ). Of note, these SLE-specific basophil parameters were independent of SLE patient treatments at the time of blood harvesting and independent of gender (data not shown). Altogether, these data validated that activated basophils, peripheral basopenia and high proportion of HLA-DR+ basophils are hallmarks of active SLE individuals. Moreover, our data strongly suggest that lupus environment drives a basophil sub-optimal activation (without a detectable degranulation response) and a basophil redistribution to SLOs. -
TABLE 1 SLE Patients and control characteristics Lupus patients Inactive Mild Active Healthy Variables All SLE (SLEDAI ≤ 1) (1 ≤ SLEDAI ≤ 4) (SLEDAI > 4) controls Demographic characteristics n 188 61 41 86 110 Age, mean ± SD, years 37.8 ± 12.3 43.4 ± 14.1 36.1 ± 10.2 34.7 ± 10.6 34.5 ± 14.9 Female Gender, n (%) 167 (89) 51 (84) 36 (88) 80 (93) 51 (47) Lupus characteristics Disease duration, mean ± SD, years 10.5 ± 8.2 11.7 ± 9.0 12.1 ± 7.5 9.1 ± 8.0 — Anti-dsDNA Ab positive, n (%) 104 (55) 10 (18) 27 (64) 67 (79) — History of lupus nephritis, n (%) 144 (77) 36 (59) 29 (66) 79 (92) — SLEDAI Mean ± SD 6.6 ± 7.6 0.0 ± 0.2 2.9 ± 1.0 13.0 ± 6.8 — Median (range) 4 (0-43) 0 (0-1) 2 (2-4) 12 (5-43) — Treatment characteristics Current prednisone dose (mg/day) Mean ± SD 23.6 ± 80.8 4.1 ± 3.9 7.2 ± 8.8 44.8 ± 115.4 — 15 mg/day or higher, n (%) 38 (20) 0 (0) 4 (9) 34 (40) — Concurrent immunosuppressive therapy (n, %) hydroxychloroquine, n (%) 159 (84) 54 (88) 38 (93) 67 (78) — mycophenolate mofetil, n (%) 50 (27) 15 (24) 16 (36) 19 (22) — cyclophosphamide, n (%) 3 (2) 0 (0) 0 (0) 3 (3) — azathioprine, n (%) 26 (14) 8 (13) 7 (17) 11 (13) — SLEDAI: Systemic Lupus Erythematosus Disease Activity Index. - PGD2/PTGDRs and CXCR4/CXCL12 axes in basophils from SLE subjects
- To decipher basophil activation and redistribution to SLOs during lupus pathogenesis, we analyzed on basophils from SLE subjects, versus HC, the expression levels of receptors for chemotactic molecules known to be dysregulated in individuals with lupus or chronic inflammatory diseases (Pellefigues, C. & Charles, N., Curr. Opin. Immunol. 25, 704-711 (2013)). Most of the screened receptor expressions were not significantly different from the ones observed on HC basophils (Table 2). Of note, Thymic Stromal Lymphopoietin Receptor (TSLP-R), IL-33 receptor (T1/ST2), C-C motif ligand receptor (CCR) 4, CCR6 and CCR7 could not be detected on basophils (Table 2).
- However, PTGDR-2 expression was increased on basophils from SLE individuals (Table 2,
FIG. 3 a ) as did its ligand titers in their plasma (11β-PGF2α levels, the main plasmatic PGD2 metabolite, are presented) (FIG. 3 b ). An inverse correlation between 11β-PGF2α titers and blood basophil counts in subjects with SLE was found (Spearman r=−0.2585, P=0.0169) (data not shown). Moreover, high levels of 11β-PGF2α were associated with increased basopenia in SLE subjects (FIG. 3 c ). Together, these data strongly suggest that PGD2 and its receptors are associated with basophil activation and extravasation during lupus. - CXCR4 expression was increased on basophils from all SLE individuals, but active SLE patients showed an even more marked increase (Table 2,
FIG. 3 d ). CXCL12 plasma titers followed the same pattern of increase as its receptor did on basophils (FIG. 3 e ). Basophil CXCR4 expression levels were negatively correlated with blood basophil count in SLE subjects (Spearman r=−0.4692, P<0.0001) (FIG. 4 b ). Moreover, in active SLE subjects, high CXCL12 titers were associated with a more pronounced basopenia (FIG. 4 c ). Endolyn (CD164) is a transmembrane syalomucin enhancing sensitivity to CXCL12 when associated to CXCR4 and is also known as a human basophil activation marker. CD164 levels on basophils from active SLE subjects followed the same expression pattern as CXCR4 and were correlated with basopenia (Spearman r=−0.4165, P=0.0029), suggesting an increased sensitivity of SLE basophils to CXCL12 in vivo (FIG. 3 f andFIG. 4 d ). Basophils are known to express CXCR4 mostly intracellularly. Analyses by imaging flow cytometry showed that SLE patient basophils had an increased CXCR4 content and that it was more externalized than in HC basophils (data not shown). -
TABLE 2 Basophil surface marker expression level relative to SLE disease activity Normalized expression levels (to CT mean) on basophils from: Chemokine Mean (±Se, n, p Mann Whitney test vs CT) or cytokine Healthy Inactive SLE Mild SLE Active SLE receptor volonteers patients patients patients analyzed CD# Ligand(s) (controls, CT) (SLEDAI ≤ 1) (1 < SLEDAI ≤ 4) (SLEDAI > 4) CCR1 CD191 CCL3, 5, 1 1.013 1.199 1.11 7, 23 (±0.14, 13, 1) (±0.17, 15, 0.78) (±0.13, 8, 0.40) (±0.18, 19, 1) CCR2 CD192 CCL2, 7, 1 1.04 1.03 1.04 8, 13, 16 (±0.11, 30, 1) (±0.15, 19, 0.89) (±0.25, 14, 0.57) (±0.2, 20, 0.58) CCR3 CD193 Eotaxin 1 0.8529 0.9268 0.9925 (CCL11, (±0.09, 39, 1) (±0.10, 10, 0.4642) (±0.11, 13, 0.9663) (±0.13, 20, 0.9681) 24, 26) CCR4 CD194 COL2, 4, ND ND ND ND 5, 17, 22 CCR5 CD195 CCL5, 3, 1 0.7726 1.377 1.031 4, 3L1 (±0.14, 6, 1) (±0.09, 5, 0.43) (±0.42, 3, 0.38) (±0.19, 7, 0.94) CCR6 CD196 CCL20 ND ND ND ND CCR7 CD197 CCL19, 21 ND ND ND ND CXCR1 CD181 IL-8 1 1.104 1.197 1.187 (±0.12, 25, 1) (±0.21, 6, 0.63) (±0.17, 6, 0.28) (±0.27, 13, 0.90) CXCR2 CD182 IL-8, 1 1.181 0.9324 1.053 CXCL1, 2, (±0.04, 53, 1) (±0.12, 27, 0.85) (±0.08, 15, 0.21) (±0.12, 37, 0.22) 3, 5 CXCR4 CD184 CXCL12 1 1.317 ** 1.279 * 2.622 **** (±0.04, 66, 1) (±0.09, 32, 0.0068) (±0.11, 20, 0.0385) (±0.42, 51, <0.001) PTGDR-2 CD294 PGD2 1 1.404 1.329 * 1.328 * (CRTH2) (±0.06, 71, 1) (±0.11,48, 0.0091) ** (±0.13, 31, 0.0446) (±0.11, 60, 0.0493) Endolyn CD164 CXCR4 1 1.281 * 1.158 1.873 **** (±0.05, 33, 1) (±0.11, 15, 0.0207) (±0.11, 7, 0.0943) (±0.18, 26, <0.0001) TSLP-R — TSLP ND ND ND ND IL33-R T1/ST2 IL33 ND ND ND ND Abbreviations used: SE: Standard Error; ND: Not Detected; CD: Cluster of Differentiation; CT: controls; CCL: C-C motif ligand; CCR: C-C motif ligand receptor; CXCL: C-X-C motif ligand; CXCR: C-X-C motif ligand receptor; CRTH2: Chemoattractant Receptor-homologous molecule expressed on Th2 cells (DP2, PTGDR-2); PGD2: Prostaglandin D2; PTGDR: PGD2 receptor; TSLP: Thymic stromal lymphopoietin (-R : receptor); Statistical analyses were by Mann-Whitney tests. *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001. - CXCL12 is described as one of the most overexpressed gene during peritoneal dialysis and is actively secreted together with PGD2 during peritonitis. To study human basophil migration in vivo, we analyzed them both in blood and in peritoneal dialysis fluid from patients being treated for a non-sterile peritonitis. CXCR4 expression was dramatically increased on human basophils recruited to the inflamed peritoneum as compared to their blood counterparts (data not shown). This basophil recruitment was associated with a peripheral basopenia (data not shown), as previously shown in active chronic idiopathic urticarial (Jain, S. Dermatology research and practice 2014, 674709), strongly suggesting that human CXCR4+ basophils can migrate in vivo to CXCL12- and PGD2-secreting inflamed tissues, and that peripheral basopenia reflects this active basophil recruitment.
- Altogether these data identified both PGD2/PTGDRs and CXCL12/CXCR4 axes as basophil activation pathways during SLE flares and which may account for their associated basopenia. Therefore, these axes may contribute to the described basophil accumulation in SLOs in individuals with active lupus.
- PGD2/PTGDRs Axis Enhances CXCR4-Dependent Basophil Migration During Lupus
- In order to evaluate the functional consequences of the above findings, ex vivo migration assays of purified basophils from HC and active SLE subjects were performed. Strikingly, SLE basophils were attracted to CXCL12 gradients while HC basophils did not (
FIG. 5 a ), reflecting their differences in CXCR4 and CD164 expression (FIG. 3 d,f ). However, no difference was detected with other common basophil chemo-attractant compounds, including PGD2 (FIG. 5 b ). Since PGD2 titers were associated with basopenia in SLE (FIG. 3 c ) and since autoreactive IgE are prevalent in active SLE subjects (FIG. 5 c and Dema, B., et al., PLoS One 9, e90424 (2014)), we next investigated if these factors could potentiate basophil migration towards CXCL12. Standard culture of purified human basophils is known to induce intracellular CXCR4 externalization, a process inhibited in the presence of IL-3. Priming purified basophils during 18 hours with 1 μM PGD2 enhanced their CXCR4 expression and their migration towards CXCL12 (FIG. 5 d,e ) and induced PTGDR-2 internalization (data not shown), without inducing their apoptosis (data not shown). This PGD2 priming induced a slight increase in the high affinity IgE receptor alpha chain (FcεRIα) expression on basophil surface, which may increase their sensitivity to IgE-dependent stimulation (data not shown). Sub-optimal anti-IgE stimulation (MacGlashan, D., Jr., Clin. Exp.Allergy 40, 1365-1377 (2010)) (i) tended to increase CXCR4 expression on basophils (FIG. 5 d ) which may influence their migration towards CXCL12 although statistical significance was not reached (FIG. 5 e ), (ii) increased PTGDR-2 expression levels on basophils (FIG. 6 a ) and (iii) did not induce basophil degranulation (data not shown). None of other tested compounds (CCL3, CXCL2 and CCL5), known to have an effect on basophils and to be dysregulated during SLE, induced an increased CXCR4 externalization ex vivo as PGD2 did (data not shown). - CXCL12 is described as one of the most overexpressed gene during peritoneal dialysis and is actively secreted together with PGD2 during peritonitis. To study human basophils migration in vivo, we analyzed them both in blood and in peritoneal dialysis fluid from patients being treated for a non-sterile peritonitis. CXCR4 was found to be dramatically increased on human basophils recruited to the inflamed peritoneum as compared to their blood counterparts (
FIG. 5 e ). This basophil recruitment was associated with a peripheral basopenia (supplementaryFIG. 5 b ), as previously shown in active chronic idiopathic urticaria. This demonstrated that human CXCR4* basophils can migrate in vivo to CXCL12- and PGD2-secreting inflamed tissues. - We next studied the mechanism by which PGD2 induced CXCR4 externalization by human basophils. Both PTGDR-1 and PTGDR-2 were cooperatively involved since antagonism of one, the other or both receptor(s) led to block CXCR4 externalization (data not shown). Moreover, blocking PTGDRs led to a decreased spontaneous CXCR4 externalization. This suggested that either ex vivo culture and/or PGD2-mediated stimulation of human basophils led them to produce PGD2 to have an autocrine effect as eosinophils do. To confirm this hypothesis, we used a specific H-PGDS inhibitor which resulted in the same inhibition of spontaneous CXCR4 externalization than the one induced by the PTGDR antagonists, and to a decreased PTGDR-2 internalization (data not shown). Together with the fact that the H-PGDS inhibitor effect was overcome only by a ten-fold higher PGD2 concentration (data not shown), we here confirmed our above hypothesis that PGD2 led to CXCR4 externalization partially by stimulating PGD2 production by basophils themselves.
- Altogether, these data strongly suggest that the PGD2/PTGDRs axis directly influences the CXCL12 sensitivity of SLE patient basophils by increasing both their CXCR4 expression and externalization, and that lupus environment (including autoreactive IgE, CXCL12 and PGD2) facilitates this cross-talk resulting in basophil extravasation and peripheral basopenia. Thus, PGD2 might be required to allow CXCR4-dependent basophil migration to SLOs in SLE individuals. Indeed, both PGD2/PTGDRs and CXCL12/CXCR4 axes were associated with basopenia and disease activity in lupus subjects (
FIG. 3 ). - CXCR4/CXCL12 and PGD2/PTGDRs axes in Lyn−/− lupus-prone mice
- We previously showed that aged Lyn−/− mice develop a basophil-
dependent T H2 bias contributing to an IgE-, IL-4- and basophil-dependent lupus-like nephritis (Charles, N. et al., Nat. Med. 16, 701-707 (2010); Charles, N., et al.,Immunity 30, 533-543 (2009)). In this lupus-like disease model, basophils accumulate in SLOs leading to an amplification loop of the disease (Charles, N., et al.,Immunity 30, 533-543 (2009)). - We next assessed whether this mouse model was involving both CXCL12/CXCR4 and PGD2/PTGDRs axes as SLE subjects did. In ex vivo migration assays, Lyn−/− spleen basophils migrated towards CXCL12 whereas their WT counterparts did not (
FIG. 7 a ) mimicking the observed differences between SLE subjects and HC (FIG. 5 a ). CXCR4 expression levels were increased on Lyn−/− basophils from blood, bone marrow (BM) and SLOs as compared to their WT counterparts in aged animals (FIG. 7 b ). Moreover, CXCR4 expression was increased on WT and Lyn−/− basophils from SLOs as compared to their blood counterparts suggesting an involvement of CXCR4 in their accumulation in these organs (FIG. 7 b ). CXCL12 intraperitoneal (ip) injection in WT mice induced in vivo basophil migration to the injection site (FIG. 7 c ) and to the draining mesenteric lymph nodes (mLN) (FIG. 8 a ). - In vivo i.p. injection of PGD2 increased CXCR4 expression on mLN Lyn−/− basophils (
FIG. 7 d ), as it did ex vivo on human basophils (FIG. 5 d ), and drove their accumulation in SLOs and peritoneum (FIG. 7 e andFIG. 8 b,c ). Moreover, in vivo ip injection of PGD2 in Lyn−/− mice led to a significant, but transient, peripheral basopenia when compared to steady state conditions (data not shown) as observed in peritoneal dialysis patients (data not shown). This PGD2-induced basophil recruitment was strictly dependent on the CXCL12/CXCR4 axis since co-injection with AMD3100, a specific antagonist of CXCR4, completely abolished basophil recruitment both in SLOs and peritoneum (FIG. 7 e andFIG. 8 b,c ). In mice, PGD2-induced CXCR4 up-regulation was as well mediated by both PTGDR-1 and PTGDR-2 (CRTH2), as shown by the effects of their specific agonists (BW245c and DK-PGD2, respectively) on spleen WT basophils ex vivo (FIG. 7 f ). Both agonists induced a significant but much lower increase in CXCR4 expression on other WT splenocytes including T and B cells (data not shown). - PTGDR-1 is known to induce cyclic adenosine monophosphate (cAMP) production upon engagement by PGD2. We next analyzed the effect of a membrane permeable cAMP (N6,2′-O-dibutyryl-
adenosine 3′:5′-cyclic monophosphate (db-cAMP)) on CXCR4 externalization by mouse WT spleen basophils ex vivo. Basophils externalized CXCR4 upon db-cAMP exposure (FIG. 9 a ) with a 100 fold higher sensitivity than T cells to this compound (FIG. 9 b ). PGD2 was unable to induce enough cAMP through PTGDR-1 to lead to CXCR4 externalization by T cells in these settings, unlike what was observed on basophils (FIG. 9 a,b ). Dose response experiments of each PTGDR specific agonists in the presence or not of H-PGDS inhibitor suggested again that both PTGDRs were able to cooperatively induce CXCR4 externalization on basophils through PTGDR-2-induced PGD2 synthesis acting in an autocrine way on PTGDR-1-mediated cAMP production (FIG. 9 c ). - These results strongly suggest that in Lyn−/− old mice, as in SLE subjects, PGD2 enhances in vivo CXCL12-dependent basophil accumulation in inflamed tissues and SLOs by modulating their CXCR4 expression levels through the activation of both PTGDR-1 and PTGDR-2.
- Therefore, a more chronic exposure to PGD2 in lupus-prone mice before they start developing the disease should lead to a chronic accumulation of basophils in SLOs, an increased number of autoreactive plasma cells and to an acceleration of disease development. To verify this hypothesis, we repeatedly injected ip PGD2 to young (12 weeks-old) Lyn−/− mice every two days over ten days. As expected, basophils increased their CXCR4 expression levels (data not shown) and accumulated systemically in SLOs (
FIG. 10 a,b ) where they were activated as shown by their increased IA-IE expression (FIG. 10 c ). This was associated with an increased proportion of CD19+ CD138+ plasma cells in SLOs (FIG. 10 d,e ), resulting in an increased deposition of immune complexes in the kidney as shown by C3 and IgG deposition quantification (FIG. 10 f ). Consequently, nearly all the PGD2 injected Lyn−/− mice had increased albuminuria unlike their PBS-injected counterparts at the end of the protocol (FIG. 10 g ). Other immune cell types analyzed didn't show any significant increase in their CXCR4 surface expression (data not shown). Importantly, this PGD2-induced lupus-like disease acceleration was dependent on basophils since antibody-mediated (MAR-1) basophil depletion during the whole protocol led to a complete rescue of the PGD2 effects on disease development (FIG. 10 b-e ). These results confirmed that PGD2, by enabling CXCR4-dependent basophil accumulation in SLOs, contributes to lupus-like disease and to autoantibody-mediated kidney damage. - Targeting the PGD2 axis reduces CXCR4-mediated basophil accumulation in SLOs and dampens lupus-like disease
- Targeting the CXCL12/CXCR4 axis in murine lupus has already been described and showed some efficacy on disease activity (Balabanian, K., et al., J. Immunol. 170, 3392-3400 (2003), Wang, A., et al., J. Immunol. 182, 4448-4458 (2009)). However, CXCR4 antagonism (with AMD3100), initially developed as an anti-HIV drug, is known to induce a release of hematopoietic stem cells and interfere with homeostatic functions (Devi, S. et al. J. Exp. Med. 210, 2321-2336, (2013), Hummel, S. et al., Curr. Opin. Hematol. 21, 29-36 (2014)). Preventing the CXCR4 up-regulation on basophils from lupus-prone Lyn−/− mice by blocking the PGD2/PTGDRs axis seemed a safer approach to disable the basophil-dependent amplification loop of autoantibody production in SLOs.
- Then, we treated aged Lyn−/− and WT mice by oral gavage with both specific antagonists of PTGDR-1 and PTGDR-2, Laropiprant and CAY10471, respectively, at a dose of 5 mg/kg each, twice daily for ten days. This treatment led to a dramatic reduction in basophil numbers in SLOs of Lyn−/− animals (
FIG. 12 a,b ) associated with a decreased CXCR4 expression on spleen basophils (FIG. 12 c ). Of note, BM and blood basophil proportions were not affected by the treatment (FIG. 13 a,b ). These results validated the approach consisting of disabling basophil accumulation in SLOs by targeting the PTGDRs. - As expected, this reduction in basophil accumulation was associated with a significant decrease of CD19+CD138+ short-lived plasma cell numbers (
FIG. 12 d andFIG. 13 c ). Strikingly, proportions of all other immune cell populations analyzed (B cells, neutrophils, Ly6C+ monocytes, and Ly6C− monocytes) remained unaffected by the treatment as did their CXCR4 expression levels (data not shown). PTGDRs blockade in Lyn−/− animals, by disabling basophil accumulation in SLOs, decreased their autoantibody titers (FIG. 12 e andFIG. 13 d ) and theirT H2 bias as measured by total IgE plasma concentrations (FIG. 12 f ). Consequently, this treatment allowed as well a significant decrease in the kidney content of C3 and IgG deposits (FIG. 11 ) and the pro-inflammatory cytokines IL-4 and IL-1P (FIG. 12 g,h ). Therefore, a short-term treatment with PTGDRs antagonists allowed an efficient dampening in the disease activity observed in our lupus-prone animals. - Altogether, these results suggest that aiming the PGD2/PTGDRs axis could be a valuable new therapeutic approach in SLE. Indeed, PTGDRs blockade, by breaking the CXCL12-dependent basophil homing to SLOs, might turn-off the basophil-dependent amplification loop of autoantibody production, efficiently preventing flares and subsequent organ damage in SLE (
FIG. 14 ).
Claims (15)
1. A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist.
2. The method according to claim 1 , wherein said antagonist is a small molecule antagonist.
4. The method according to claim 1 , wherein said PTGDR-1 antagonist is laropiprant.
5. The method according to claim 1 , wherein said PTGDR-1 antagonist is used in combination with at least a PTGDR-2 antagonist.
6. The method according to claim 5 , wherein said PTGDR-2 antagonist has formula formula (VIII)
7. The method according to claim 6 , wherein said PTGDR-2 antagonist is CAY10471 (TM30089).
8. The method according to claim 5 , wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in a single pharmaceutical composition.
9. The method according to claim 5 , wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in separate pharmaceutical compositions for simultaneous use, separate use, or use spread over time.
10. The method according to claim 1 , wherein said PTGDR-1 antagonist is a dual PTGDR-1/PTGDR-2 antagonist.
11. A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a pharmaceutical composition comprising a PTGDR-1 antagonist and a PTGDR-2 antagonist, or a dual PTGDR-1/PTGDR-2 antagonist.
12. A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist and a PTGDR-2 antagonist as a combined preparation for simultaneous use, separate use, or use spread over time.
13. A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-2 antagonist.
14. The method according to claim 1 , wherein the PTGDR-1 antagonist prevents basophil homing to secondary lymphoid organs.
15. The method according to claim 1 , wherein the PTGDR-1 antagonist prevents, limits the extent or reduces the increase in autoantibody titers and/or the occurrence of SLE flares and/or organ damages.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/068,682 US20230330062A1 (en) | 2015-02-13 | 2022-12-20 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305222.0 | 2015-02-13 | ||
EP15305222 | 2015-02-13 | ||
PCT/EP2016/053069 WO2016128565A1 (en) | 2015-02-13 | 2016-02-12 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US201715549401A | 2017-08-08 | 2017-08-08 | |
US16/011,723 US20180296528A1 (en) | 2015-02-13 | 2018-06-19 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US16/846,611 US11559513B2 (en) | 2015-02-13 | 2020-04-13 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US18/068,682 US20230330062A1 (en) | 2015-02-13 | 2022-12-20 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/846,611 Continuation US11559513B2 (en) | 2015-02-13 | 2020-04-13 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230330062A1 true US20230330062A1 (en) | 2023-10-19 |
Family
ID=52596905
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/549,401 Abandoned US20180021302A1 (en) | 2015-02-13 | 2016-02-12 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US16/011,723 Abandoned US20180296528A1 (en) | 2015-02-13 | 2018-06-19 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US16/846,611 Active US11559513B2 (en) | 2015-02-13 | 2020-04-13 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US18/068,682 Abandoned US20230330062A1 (en) | 2015-02-13 | 2022-12-20 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/549,401 Abandoned US20180021302A1 (en) | 2015-02-13 | 2016-02-12 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US16/011,723 Abandoned US20180296528A1 (en) | 2015-02-13 | 2018-06-19 | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US16/846,611 Active US11559513B2 (en) | 2015-02-13 | 2020-04-13 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus |
Country Status (4)
Country | Link |
---|---|
US (4) | US20180021302A1 (en) |
EP (2) | EP4420734A2 (en) |
JP (1) | JP6770522B2 (en) |
WO (1) | WO2016128565A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022046605A1 (en) * | 2020-08-25 | 2022-03-03 | City Of Hope | Compositions and methods for g-protein-coupled receptor 44 detection |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3631824A1 (en) | 1986-02-21 | 1988-03-31 | Bayer Ag | CYCLOALKANO (1.2-B) INDOL-SULFONAMIDE |
CA2225250C (en) | 1995-06-21 | 2005-03-22 | Shionogi & Co., Ltd. | Bicyclic amino derivatives and pgd2 antagonist containing the same |
ATE295360T1 (en) | 1996-12-12 | 2005-05-15 | Shionogi & Co | CONDENSED HETEROCYCLIC BENZENECARBONIC ACID AMIDE DERIVATIVES AND PGD2 ANTAGONISTS CONTAINING SAME |
CZ297324B6 (en) | 1996-12-13 | 2006-11-15 | Shionogi & Co., Ltd. | Benzothiophenecarboxamide derivatives and PGD2 antagonists comprising them |
DE19757983A1 (en) | 1997-12-24 | 1999-07-01 | Bayer Yakuhin Ltd | Thermodynamically stable form of (r) -3 [[(4-fluorophenyl) sulfonyl] amino] -1,2,3,4-tetrahydro-9H-carbazole-0-propanoic acid (Ramatroban) |
WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
CA2402174A1 (en) | 2000-03-09 | 2001-09-13 | Ono Pharmaceutical Co., Ltd. | Indole derivatives, process for preparation of the same and use thereof |
US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
DE60215000T2 (en) | 2001-05-23 | 2007-08-09 | Merck Frosst Canada & Co, Kirkland | Dihydropyrroloil [1,2-a] indole and tetrahydropyridol [1,2-a] indole derivatives as prostaglandin D2 receptor antagonists |
JPWO2003022814A1 (en) | 2001-09-07 | 2004-12-24 | 小野薬品工業株式会社 | Indole derivative compound |
AR038136A1 (en) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS |
SE0200356D0 (en) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200411D0 (en) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
WO2003078409A1 (en) | 2002-03-19 | 2003-09-25 | Ono Pharmaceutical Co., Ltd. | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient |
AU2003231513A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Pgd2 receptor antagonist |
AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (en) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (en) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
JP2006508077A (en) | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | PGD2 receptor antagonist for the treatment of inflammatory diseases |
AU2003269327A1 (en) | 2002-10-21 | 2004-05-04 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
JP4457017B2 (en) | 2002-12-20 | 2010-04-28 | アムジエン・インコーポレーテツド | Asthma and allergic inflammation modulators |
EP1435356A1 (en) | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
AR041089A1 (en) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS |
US20070054951A1 (en) | 2003-05-20 | 2007-03-08 | Lianhai Li | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists |
SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (en) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
SA04250253B1 (en) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd |
WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
WO2005040114A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds having crth2 antagonist activity |
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
GB2407318A (en) * | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
SE0303180D0 (en) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
DK1725553T3 (en) | 2004-03-11 | 2008-08-18 | Actelion Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
KR20070002085A (en) | 2004-04-07 | 2007-01-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
JP2007533725A (en) | 2004-04-20 | 2007-11-22 | ファイザー・インク | Neuropathic pain treatment method using CRTH2 receptor antagonist |
MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
WO2006026273A2 (en) | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
WO2006034419A2 (en) | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
CA2621310C (en) | 2005-09-27 | 2014-08-12 | Shionogi & Co., Ltd. | Sulfonamide derivative having pgd2 receptor antagonistic activity |
WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
GT200600457A (en) | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | DIHYDROGEN PHOSPHATE SALT AS ANTAGONIST OF PROSTAGLANDINA D2 RECEPTOR |
GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
SI2057115T1 (en) | 2006-08-21 | 2013-02-28 | Array Biopharma, Inc. | 4-substituted phenoxyphenylacetic acid derivatives |
AU2007336077A1 (en) * | 2006-12-20 | 2008-06-26 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
WO2008123349A1 (en) | 2007-03-27 | 2008-10-16 | Shionogi & Co., Ltd. | Method for producing n-phenyl-n'-phenylsulfonylpiperazine derivative |
EP2197438B1 (en) * | 2007-10-10 | 2015-07-15 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Heterocyclic compounds as crth2 receptor antagonists |
ES2471919T3 (en) * | 2007-12-19 | 2014-06-27 | Amgen, Inc | Phenylacetic acid derivatives as inflammation modulators |
EP2379535B1 (en) * | 2008-12-22 | 2016-06-15 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
SG177736A1 (en) * | 2009-07-31 | 2012-02-28 | Panmira Pharmaceuticals Llc | Dermal formulations of dp2 receptor antagonists |
AR088204A1 (en) | 2011-09-29 | 2014-05-14 | Shionogi & Co | MEDICINES FOR THE TREATMENT OF ALLERGY RHINITIS THAT INCLUDE A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
MX2015012326A (en) | 2013-03-15 | 2016-03-08 | Genentech Inc | Anti-crth2 antibodies and their use. |
-
2016
- 2016-02-12 EP EP24172770.0A patent/EP4420734A2/en active Pending
- 2016-02-12 JP JP2017541997A patent/JP6770522B2/en active Active
- 2016-02-12 WO PCT/EP2016/053069 patent/WO2016128565A1/en active Application Filing
- 2016-02-12 US US15/549,401 patent/US20180021302A1/en not_active Abandoned
- 2016-02-12 EP EP16704226.6A patent/EP3256121B1/en active Active
-
2018
- 2018-06-19 US US16/011,723 patent/US20180296528A1/en not_active Abandoned
-
2020
- 2020-04-13 US US16/846,611 patent/US11559513B2/en active Active
-
2022
- 2022-12-20 US US18/068,682 patent/US20230330062A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016128565A1 (en) | 2016-08-18 |
US20200261413A1 (en) | 2020-08-20 |
US20180021302A1 (en) | 2018-01-25 |
EP3256121A1 (en) | 2017-12-20 |
JP2018506537A (en) | 2018-03-08 |
JP6770522B2 (en) | 2020-10-14 |
EP4420734A2 (en) | 2024-08-28 |
EP3256121B1 (en) | 2024-08-07 |
US20180296528A1 (en) | 2018-10-18 |
US11559513B2 (en) | 2023-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | IgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis | |
US10940126B2 (en) | Inhibition of IL-8 in the treatment of pain and/or bone loss | |
TWI784988B (en) | Methods of treating inflammatory conditions | |
Svensson et al. | Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal | |
AU2010364324B2 (en) | Compositions and methods for treating or preventing lupus | |
Candelier et al. | Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle | |
US10545134B2 (en) | RAC1 inhibitors for the treatment of Alport glomerular disease | |
CN112807427A (en) | Use of an anti-CXCL 10 antibody for the preparation of a medicament for treating an inflammatory disease in a subject | |
TWI572358B (en) | Alpha-enolase specific antibodies and methods of use in immune diseases | |
US20230330062A1 (en) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus | |
Mao et al. | HDAC2 exacerbates rheumatoid arthritis progression via the IL‐17‐CCL7 signaling pathway | |
Askanase et al. | New and future therapies: changes in the therapeutic armamentarium for SLE | |
US20240117023A1 (en) | Method | |
US20210238295A1 (en) | Compositions and methods for treating abdominal aortic aneurysm | |
US9511086B2 (en) | Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis | |
US20210246442A1 (en) | Compositions and methods for treating or preventing lupus | |
EP3316886B1 (en) | Methods and compounds for the alleviation and/or prevention of pain | |
兼光直敏 et al. | Research on Physiological and Pathophysiological Functions of Chemokines for the Purpose of New Drug Development Targeting Chemokine Signaling in a Chronic Kidney Disease | |
JP6846808B2 (en) | Treatment, diagnosis and screening with CARD14 | |
WO2023183822A1 (en) | Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure | |
WO2022221602A2 (en) | Compositions and methods for treating and/or preventing lung injury | |
Cruz | Functional Regulation of Interleukin-17 Receptor Signaling | |
Martin | Molecular and cellular mechanisms of increased angiogenesis in multiple myeloma: a role for CXCL12. | |
Garg | Feedback inhibition of IL-17 receptor signal transduction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |